HRP20180413T1 - Inhibitori kinaza koji reguliraju signalne puteve u apoptozi - Google Patents
Inhibitori kinaza koji reguliraju signalne puteve u apoptozi Download PDFInfo
- Publication number
- HRP20180413T1 HRP20180413T1 HRP20180413TT HRP20180413T HRP20180413T1 HR P20180413 T1 HRP20180413 T1 HR P20180413T1 HR P20180413T T HRP20180413T T HR P20180413TT HR P20180413 T HRP20180413 T HR P20180413T HR P20180413 T1 HRP20180413 T1 HR P20180413T1
- Authority
- HR
- Croatia
- Prior art keywords
- cyclopropyl
- triazol
- phenyl
- carboxamide
- picolinamide
- Prior art date
Links
- 230000006907 apoptotic process Effects 0.000 title 1
- 229940043355 kinase inhibitor Drugs 0.000 title 1
- 239000003757 phosphotransferase inhibitor Substances 0.000 title 1
- 125000004432 carbon atom Chemical group C* 0.000 claims 18
- 150000001875 compounds Chemical class 0.000 claims 17
- 239000003814 drug Substances 0.000 claims 15
- 229940124597 therapeutic agent Drugs 0.000 claims 15
- 125000000217 alkyl group Chemical group 0.000 claims 11
- 125000000753 cycloalkyl group Chemical group 0.000 claims 10
- 125000005843 halogen group Chemical group 0.000 claims 10
- 125000000623 heterocyclic group Chemical group 0.000 claims 8
- 125000001072 heteroaryl group Chemical group 0.000 claims 6
- 125000003545 alkoxy group Chemical group 0.000 claims 5
- 125000003118 aryl group Chemical group 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 5
- 125000001424 substituent group Chemical group 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 4
- 125000004043 oxo group Chemical group O=* 0.000 claims 4
- IBBMAWULFFBRKK-UHFFFAOYSA-N picolinamide Chemical compound NC(=O)C1=CC=CC=N1 IBBMAWULFFBRKK-UHFFFAOYSA-N 0.000 claims 4
- 208000018522 Gastrointestinal disease Diseases 0.000 claims 3
- 239000003242 anti bacterial agent Substances 0.000 claims 3
- 229940088710 antibiotic agent Drugs 0.000 claims 3
- 208000035475 disorder Diseases 0.000 claims 3
- 229910052739 hydrogen Inorganic materials 0.000 claims 3
- 239000001257 hydrogen Substances 0.000 claims 3
- 125000004435 hydrogen atom Chemical class [H]* 0.000 claims 3
- 208000030159 metabolic disease Diseases 0.000 claims 3
- GOGXLGAITRQZTK-IBGZPJMESA-N 3-(4-cyclopropylimidazol-1-yl)-N-[6-[4-[(1S)-1-phenylethyl]-1,5-dihydro-1,2,4-triazol-3-yl]pyridin-2-yl]benzamide Chemical compound C1(CC1)C=1N=CN(C=1)C=1C=C(C(=O)NC2=NC(=CC=C2)C2=NNCN2[C@@H](C)C2=CC=CC=C2)C=CC=1 GOGXLGAITRQZTK-IBGZPJMESA-N 0.000 claims 2
- UIQLWDNHZZPCHD-UHFFFAOYSA-N 4-chloro-5-(6-cyclopropylpyridin-3-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-2-fluorobenzamide Chemical compound FC1=CC(Cl)=C(C=2C=NC(=CC=2)C2CC2)C=C1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 UIQLWDNHZZPCHD-UHFFFAOYSA-N 0.000 claims 2
- HSSJHMGCYYTGPL-UHFFFAOYSA-N 5-(6-cyclopropylpyridin-3-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-2,4-difluorobenzamide Chemical compound FC1=CC(F)=C(C=2C=NC(=CC=2)C2CC2)C=C1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 HSSJHMGCYYTGPL-UHFFFAOYSA-N 0.000 claims 2
- PRHILGIXJLEDBO-UHFFFAOYSA-N 6-(6-cyclopropylpyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C=CC(C=2C=NC(=CC=2)C2CC2)=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 PRHILGIXJLEDBO-UHFFFAOYSA-N 0.000 claims 2
- 208000024172 Cardiovascular disease Diseases 0.000 claims 2
- 206010019280 Heart failures Diseases 0.000 claims 2
- 208000022559 Inflammatory bowel disease Diseases 0.000 claims 2
- 239000000935 antidepressant agent Substances 0.000 claims 2
- 229940005513 antidepressants Drugs 0.000 claims 2
- 239000002220 antihypertensive agent Substances 0.000 claims 2
- 229940030600 antihypertensive agent Drugs 0.000 claims 2
- 239000003524 antilipemic agent Substances 0.000 claims 2
- 239000002249 anxiolytic agent Substances 0.000 claims 2
- 229940049706 benzodiazepine Drugs 0.000 claims 2
- 125000003310 benzodiazepinyl group Chemical class N1N=C(C=CC2=C1C=CC=C2)* 0.000 claims 2
- 201000010099 disease Diseases 0.000 claims 2
- 208000021302 gastroesophageal reflux disease Diseases 0.000 claims 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 2
- 230000004199 lung function Effects 0.000 claims 2
- BQJCRHHNABKAKU-KBQPJGBKSA-N morphine Chemical compound O([C@H]1[C@H](C=C[C@H]23)O)C4=C5[C@@]12CCN(C)[C@@H]3CC5=CC=C4O BQJCRHHNABKAKU-KBQPJGBKSA-N 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 claims 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 claims 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 claims 1
- UYURQXWMXAOMBK-UHFFFAOYSA-N 1-[3-[[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]carbamoyl]phenyl]-5-methylimidazole-4-carboxylic acid Chemical compound CC1=C(C(O)=O)N=CN1C1=CC=CC(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 UYURQXWMXAOMBK-UHFFFAOYSA-N 0.000 claims 1
- PWRAOHMWIGDSPU-UHFFFAOYSA-N 2-(6-cyclopropylpyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-4-carboxamide Chemical compound C=1C=NC(C=2C=NC(=CC=2)C2CC2)=CC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 PWRAOHMWIGDSPU-UHFFFAOYSA-N 0.000 claims 1
- ANEKNGXSOTWRDL-UHFFFAOYSA-N 2-(6-cyclopropylpyridin-3-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]pyridine-4-carboxamide Chemical compound C=1C=NC(C=2C=NC(=CC=2)C2CC2)=CC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 ANEKNGXSOTWRDL-UHFFFAOYSA-N 0.000 claims 1
- ZILVNHNSYBNLSZ-UHFFFAOYSA-N 2-(diaminomethylideneamino)guanidine Chemical compound NC(N)=NNC(N)=N ZILVNHNSYBNLSZ-UHFFFAOYSA-N 0.000 claims 1
- HFWQWJJXZZFIMY-HNNXBMFYSA-N 3-(4,5-dimethylimidazol-1-yl)-n-[6-[4-[(2s)-1,1,1-trifluoropropan-2-yl]-1,2,4-triazol-3-yl]pyridin-2-yl]benzamide Chemical compound FC(F)(F)[C@H](C)N1C=NN=C1C1=CC=CC(NC(=O)C=2C=C(C=CC=2)N2C(=C(C)N=C2)C)=N1 HFWQWJJXZZFIMY-HNNXBMFYSA-N 0.000 claims 1
- VOTLSCJEAIOEMI-UHFFFAOYSA-N 3-(4-cyclopropyl-1,2,4-triazol-3-yl)aniline Chemical compound NC1=CC=CC(C=2N(C=NN=2)C2CC2)=C1 VOTLSCJEAIOEMI-UHFFFAOYSA-N 0.000 claims 1
- ORYZBUNRYCVWJA-UHFFFAOYSA-N 3-(4-cyclopropylimidazol-1-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-2-methylbenzamide Chemical compound CC1=C(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)C=CC=C1N(C=1)C=NC=1C1CC1 ORYZBUNRYCVWJA-UHFFFAOYSA-N 0.000 claims 1
- CLWNEOXYSGKKIM-UHFFFAOYSA-N 3-(4-cyclopropylimidazol-1-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-4-methoxybenzamide Chemical compound COC1=CC=C(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)C=C1N(C=1)C=NC=1C1CC1 CLWNEOXYSGKKIM-UHFFFAOYSA-N 0.000 claims 1
- QHAUPWYENQTMNO-UHFFFAOYSA-N 3-(4-cyclopropylimidazol-1-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-4-methylbenzamide Chemical compound CC1=CC=C(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)C=C1N(C=1)C=NC=1C1CC1 QHAUPWYENQTMNO-UHFFFAOYSA-N 0.000 claims 1
- SVYPENLGHUOCQD-UHFFFAOYSA-N 3-(4-cyclopropylimidazol-1-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-5-fluorobenzamide Chemical compound C=1C(F)=CC(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)=CC=1N(C=1)C=NC=1C1CC1 SVYPENLGHUOCQD-UHFFFAOYSA-N 0.000 claims 1
- ZRGFHFVCJIZWJJ-UHFFFAOYSA-N 3-(4-cyclopropylimidazol-1-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-5-methylbenzamide Chemical compound C=1C(C)=CC(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)=CC=1N(C=1)C=NC=1C1CC1 ZRGFHFVCJIZWJJ-UHFFFAOYSA-N 0.000 claims 1
- WUSUSCGYDUUQMW-UHFFFAOYSA-N 3-(4-cyclopropylimidazol-1-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]benzamide Chemical compound C=1C=CC(N2C=C(N=C2)C2CC2)=CC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 WUSUSCGYDUUQMW-UHFFFAOYSA-N 0.000 claims 1
- JFRSLEBBTJAYKT-UHFFFAOYSA-N 3-(4-cyclopropylimidazol-1-yl)-n-[6-(4-propan-2-yl-1,2,4-triazol-3-yl)pyridin-2-yl]benzamide Chemical compound CC(C)N1C=NN=C1C1=CC=CC(NC(=O)C=2C=C(C=CC=2)N2C=C(N=C2)C2CC2)=N1 JFRSLEBBTJAYKT-UHFFFAOYSA-N 0.000 claims 1
- VXKNIUIYRGFKTJ-UHFFFAOYSA-N 3-(4-cyclopropyltriazol-1-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]benzamide Chemical compound C=1C=CC(N2N=NC(=C2)C2CC2)=CC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 VXKNIUIYRGFKTJ-UHFFFAOYSA-N 0.000 claims 1
- SJKYOXDWFILZJJ-UHFFFAOYSA-N 3-(6-cyclopropylpyridin-3-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]benzamide Chemical compound C=1C=CC(C=2C=NC(=CC=2)C2CC2)=CC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 SJKYOXDWFILZJJ-UHFFFAOYSA-N 0.000 claims 1
- OPVNUCOTCYNSIT-UHFFFAOYSA-N 4-(2-aminopyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound NC1=NC=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 OPVNUCOTCYNSIT-UHFFFAOYSA-N 0.000 claims 1
- WBEYBRYJAQKIBV-UHFFFAOYSA-N 4-(2-aminopyrimidin-5-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C1=NC(N)=NC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 WBEYBRYJAQKIBV-UHFFFAOYSA-N 0.000 claims 1
- CPRSZYIJYCFPHV-UHFFFAOYSA-N 4-(2-cyclopropylpyrimidin-5-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(=NC=2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 CPRSZYIJYCFPHV-UHFFFAOYSA-N 0.000 claims 1
- ZLXNFEXYBUQYRS-UHFFFAOYSA-N 4-(3-aminopyrrolidin-1-yl)-n-[3-(4-methyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound CN1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)N2CC(N)CC2)=C1 ZLXNFEXYBUQYRS-UHFFFAOYSA-N 0.000 claims 1
- VDHWXRVYARKNEN-UHFFFAOYSA-N 4-(3-cyclopropyl-1,2,4-oxadiazol-5-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2ON=C(N=2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 VDHWXRVYARKNEN-UHFFFAOYSA-N 0.000 claims 1
- YHJZYWIEDZFZTC-UHFFFAOYSA-N 4-(3-cyclopropyl-1,2,4-triazol-1-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(N2N=C(N=C2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 YHJZYWIEDZFZTC-UHFFFAOYSA-N 0.000 claims 1
- ATWVMVICZNEPIS-UHFFFAOYSA-N 4-(3-methylimidazol-4-yl)-n-[3-(4-methyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound CN1C=NC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C)=C1 ATWVMVICZNEPIS-UHFFFAOYSA-N 0.000 claims 1
- COAIOYUZIYDHHI-UHFFFAOYSA-N 4-(4-chloroimidazol-1-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C1=NC(Cl)=CN1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 COAIOYUZIYDHHI-UHFFFAOYSA-N 0.000 claims 1
- PVPSFOMUSUJVJD-UHFFFAOYSA-N 4-(4-cyclopropyl-2-methylimidazol-1-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound CC1=NC(C2CC2)=CN1C(C=1)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 PVPSFOMUSUJVJD-UHFFFAOYSA-N 0.000 claims 1
- MILXKDOAYPXJDU-UHFFFAOYSA-N 4-(4-cyclopropyl-2-methylimidazol-1-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]pyridine-2-carboxamide Chemical compound CC1=NC(C2CC2)=CN1C(C=1)=CC=NC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 MILXKDOAYPXJDU-UHFFFAOYSA-N 0.000 claims 1
- PVSUBIMAWRQDND-UHFFFAOYSA-N 4-(4-cyclopropylimidazol-1-yl)-N-[3-[4-(1-phenylethyl)-1,5-dihydro-1,2,4-triazol-3-yl]phenyl]pyridine-2-carboxamide Chemical compound C1(CC1)C=1N=CN(C=1)C1=CC(=NC=C1)C(=O)NC1=CC(=CC=C1)C1=NNCN1C(C)C1=CC=CC=C1 PVSUBIMAWRQDND-UHFFFAOYSA-N 0.000 claims 1
- ZGCMQKWOUIMBEP-UHFFFAOYSA-N 4-(4-cyclopropylimidazol-1-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(N2C=C(N=C2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 ZGCMQKWOUIMBEP-UHFFFAOYSA-N 0.000 claims 1
- JUMZLCHBKTTYGI-UHFFFAOYSA-N 4-(4-cyclopropylimidazol-1-yl)-n-[3-(4-phenyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(N2C=C(N=C2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1=CC=CC=C1 JUMZLCHBKTTYGI-UHFFFAOYSA-N 0.000 claims 1
- UIZCAIJJBDQQHD-UHFFFAOYSA-N 4-(4-cyclopropylimidazol-1-yl)-n-[3-(4-propan-2-yl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound CC(C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)N2C=C(N=C2)C2CC2)=C1 UIZCAIJJBDQQHD-UHFFFAOYSA-N 0.000 claims 1
- JDDADOSVPOCIPT-UHFFFAOYSA-N 4-(4-cyclopropylimidazol-1-yl)-n-[3-(4-pyridin-2-yl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(N2C=C(N=C2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1=CC=CC=N1 JDDADOSVPOCIPT-UHFFFAOYSA-N 0.000 claims 1
- FHZPUSNFFYCNBN-UHFFFAOYSA-N 4-(4-cyclopropylimidazol-1-yl)-n-[3-(4-pyridin-3-yl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(N2C=C(N=C2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1=CC=CN=C1 FHZPUSNFFYCNBN-UHFFFAOYSA-N 0.000 claims 1
- NBLRKANLNAHDQU-UHFFFAOYSA-N 4-(4-cyclopropylimidazol-1-yl)-n-[3-(4-pyridin-4-yl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(N2C=C(N=C2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1=CC=NC=C1 NBLRKANLNAHDQU-UHFFFAOYSA-N 0.000 claims 1
- FZNYJFSIXYOFRP-UHFFFAOYSA-N 4-(4-cyclopropylimidazol-1-yl)-n-[3-(4-pyrimidin-5-yl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(N2C=C(N=C2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1=CN=CN=C1 FZNYJFSIXYOFRP-UHFFFAOYSA-N 0.000 claims 1
- MYKKXJLOHSUFQR-UHFFFAOYSA-N 4-(4-cyclopropylimidazol-1-yl)-n-[3-[4-(1-pyridin-3-yloxypropan-2-yl)-1,2,4-triazol-3-yl]phenyl]pyridine-2-carboxamide Chemical compound C1=NN=C(C=2C=C(NC(=O)C=3N=CC=C(C=3)N3C=C(N=C3)C3CC3)C=CC=2)N1C(C)COC1=CC=CN=C1 MYKKXJLOHSUFQR-UHFFFAOYSA-N 0.000 claims 1
- LSEDGIXFBSWZKL-UHFFFAOYSA-N 4-(4-cyclopropylimidazol-1-yl)-n-[3-[4-(cyclopropylmethyl)-1,2,4-triazol-3-yl]phenyl]pyridine-2-carboxamide Chemical compound C=1C(N2C=C(N=C2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1CC1CC1 LSEDGIXFBSWZKL-UHFFFAOYSA-N 0.000 claims 1
- CWZONKSGCPUCFJ-CQSZACIVSA-N 4-(4-cyclopropylimidazol-1-yl)-n-[3-[4-[(2r)-1,1,1-trifluoropropan-2-yl]-1,2,4-triazol-3-yl]phenyl]pyridine-2-carboxamide Chemical compound FC(F)(F)[C@@H](C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)N2C=C(N=C2)C2CC2)=C1 CWZONKSGCPUCFJ-CQSZACIVSA-N 0.000 claims 1
- CWZONKSGCPUCFJ-AWEZNQCLSA-N 4-(4-cyclopropylimidazol-1-yl)-n-[3-[4-[(2s)-1,1,1-trifluoropropan-2-yl]-1,2,4-triazol-3-yl]phenyl]pyridine-2-carboxamide Chemical compound FC(F)(F)[C@H](C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)N2C=C(N=C2)C2CC2)=C1 CWZONKSGCPUCFJ-AWEZNQCLSA-N 0.000 claims 1
- STWJOSXILLUDAQ-KRWDZBQOSA-N 4-(4-cyclopropylimidazol-1-yl)-n-[3-[4-[(2s)-3-methylbutan-2-yl]-1,2,4-triazol-3-yl]phenyl]pyridine-2-carboxamide Chemical compound CC(C)[C@H](C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)N2C=C(N=C2)C2CC2)=C1 STWJOSXILLUDAQ-KRWDZBQOSA-N 0.000 claims 1
- BKFBGSVKYLQOML-UHFFFAOYSA-N 4-(4-cyclopropylimidazol-1-yl)-n-[3-[4-[1-(2,2,2-trifluoroethoxy)propan-2-yl]-1,2,4-triazol-3-yl]phenyl]pyridine-2-carboxamide Chemical compound FC(F)(F)COCC(C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)N2C=C(N=C2)C2CC2)=C1 BKFBGSVKYLQOML-UHFFFAOYSA-N 0.000 claims 1
- KMWDQIUOZZDYRN-UHFFFAOYSA-N 4-(4-cyclopropylimidazol-1-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]pyridine-2-carboxamide Chemical compound C=1C(N2C=C(N=C2)C2CC2)=CC=NC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 KMWDQIUOZZDYRN-UHFFFAOYSA-N 0.000 claims 1
- TVDPMASDODMCGQ-UHFFFAOYSA-N 4-(4-cyclopropylimidazol-1-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]quinoline-2-carboxamide Chemical compound C=1C(N2C=C(N=C2)C2CC2)=C2C=CC=CC2=NC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 TVDPMASDODMCGQ-UHFFFAOYSA-N 0.000 claims 1
- DLKPXPZUVSZPGK-UHFFFAOYSA-N 4-(4-cyclopropylphenyl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=CC(=CC=2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 DLKPXPZUVSZPGK-UHFFFAOYSA-N 0.000 claims 1
- KBRLQVBGSCHYKI-UHFFFAOYSA-N 4-(4-methylpiperazin-1-yl)-n-[3-(4-methyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C1CN(C)CCN1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C)=C1 KBRLQVBGSCHYKI-UHFFFAOYSA-N 0.000 claims 1
- HNYNGXKHKFGVBR-UHFFFAOYSA-N 4-(5-chloro-6-cyclopropylpyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound ClC1=CC(C=2C=C(N=CC=2)C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=CN=C1C1CC1 HNYNGXKHKFGVBR-UHFFFAOYSA-N 0.000 claims 1
- XMIDMDWLWJGOJO-UHFFFAOYSA-N 4-(5-chloro-6-ethylpyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C1=C(Cl)C(CC)=NC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 XMIDMDWLWJGOJO-UHFFFAOYSA-N 0.000 claims 1
- PPJNKMGNBFLTBW-UHFFFAOYSA-N 4-(5-chloropyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound ClC1=CN=CC(C=2C=C(N=CC=2)C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 PPJNKMGNBFLTBW-UHFFFAOYSA-N 0.000 claims 1
- MPPHLNGBNOKFMV-UHFFFAOYSA-N 4-(5-cyanopyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=C(C=NC=2)C#N)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 MPPHLNGBNOKFMV-UHFFFAOYSA-N 0.000 claims 1
- NGSRPODQIQEEMR-UHFFFAOYSA-N 4-(5-cyclopropyl-1,2,4-triazol-1-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(N2C(=NC=N2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 NGSRPODQIQEEMR-UHFFFAOYSA-N 0.000 claims 1
- CZIUEMXDLQZYGK-UHFFFAOYSA-N 4-(5-cyclopropyl-1,3,4-thiadiazol-2-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2SC(=NN=2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 CZIUEMXDLQZYGK-UHFFFAOYSA-N 0.000 claims 1
- VUXTTZOIFIKYIA-UHFFFAOYSA-N 4-(5-cyclopropyl-4-methyl-1,2,4-triazol-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound CN1C(C2CC2)=NN=C1C(C=1)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 VUXTTZOIFIKYIA-UHFFFAOYSA-N 0.000 claims 1
- RLGFHCROFVRTAF-UHFFFAOYSA-N 4-(5-cyclopropylpyrazin-2-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2N=CC(=NC=2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 RLGFHCROFVRTAF-UHFFFAOYSA-N 0.000 claims 1
- HZRLUTSOXHJXOK-UHFFFAOYSA-N 4-(5-cyclopropylpyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=C(C=NC=2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 HZRLUTSOXHJXOK-UHFFFAOYSA-N 0.000 claims 1
- IFASTQOSKKEWDD-UHFFFAOYSA-N 4-(5-methoxypyridin-3-yl)-n-[3-(4-methyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound COC1=CN=CC(C=2C=C(N=CC=2)C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C)=C1 IFASTQOSKKEWDD-UHFFFAOYSA-N 0.000 claims 1
- QXPYZSBTIUATJG-UHFFFAOYSA-N 4-(6-aminopyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C1=NC(N)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 QXPYZSBTIUATJG-UHFFFAOYSA-N 0.000 claims 1
- FDGVSBVOFQXYQJ-UHFFFAOYSA-N 4-(6-cyclobutylpyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(=CC=2)C2CCC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 FDGVSBVOFQXYQJ-UHFFFAOYSA-N 0.000 claims 1
- JDCRZLPHKMOKSG-UHFFFAOYSA-N 4-(6-cyclopentylpyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(=CC=2)C2CCCC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 JDCRZLPHKMOKSG-UHFFFAOYSA-N 0.000 claims 1
- IDDSYESOBQTNGY-UHFFFAOYSA-N 4-(6-cyclopropyl-5-fluoropyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound FC1=CC(C=2C=C(N=CC=2)C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=CN=C1C1CC1 IDDSYESOBQTNGY-UHFFFAOYSA-N 0.000 claims 1
- KDAQKBWZTUGFQY-UHFFFAOYSA-N 4-(6-cyclopropyloxypyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(OC3CC3)=CC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 KDAQKBWZTUGFQY-UHFFFAOYSA-N 0.000 claims 1
- HEQPLJOZGXWHRJ-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[2-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-4-yl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(=CC=2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=NC=1C1=NN=CN1C1CC1 HEQPLJOZGXWHRJ-UHFFFAOYSA-N 0.000 claims 1
- JCGCGDWQFBXIFS-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)-2-fluorophenyl]pyridine-2-carboxamide Chemical compound C1=CC=C(C=2N(C=NN=2)C2CC2)C(F)=C1NC(=O)C(N=CC=1)=CC=1C(C=N1)=CC=C1C1CC1 JCGCGDWQFBXIFS-UHFFFAOYSA-N 0.000 claims 1
- ZWUQCUNTWFRCNU-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)-4-fluorophenyl]pyridine-2-carboxamide Chemical compound C1=C(C=2N(C=NN=2)C2CC2)C(F)=CC=C1NC(=O)C(N=CC=1)=CC=1C(C=N1)=CC=C1C1CC1 ZWUQCUNTWFRCNU-UHFFFAOYSA-N 0.000 claims 1
- OSWJOKQOVKCHDS-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)-5-fluorophenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2N(C=NN=2)C2CC2)=CC(F)=CC=1NC(=O)C(N=CC=1)=CC=1C(C=N1)=CC=C1C1CC1 OSWJOKQOVKCHDS-UHFFFAOYSA-N 0.000 claims 1
- HQMYIKNYYOEUJH-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-5-methylpyridine-2-carboxamide Chemical compound CC1=CN=C(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)C=C1C(C=N1)=CC=C1C1CC1 HQMYIKNYYOEUJH-UHFFFAOYSA-N 0.000 claims 1
- PZAFLBLEILTJLN-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-6-methylpyridine-2-carboxamide Chemical compound N=1C(C)=CC(C=2C=NC(=CC=2)C2CC2)=CC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 PZAFLBLEILTJLN-UHFFFAOYSA-N 0.000 claims 1
- DXTDBGZVYUUAGG-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-7,8-dimethylquinoline-2-carboxamide Chemical compound N=1C2=C(C)C(C)=CC=C2C(C=2C=NC(=CC=2)C2CC2)=CC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 DXTDBGZVYUUAGG-UHFFFAOYSA-N 0.000 claims 1
- OHYKJIGILBYHKC-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(=CC=2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 OHYKJIGILBYHKC-UHFFFAOYSA-N 0.000 claims 1
- XQPSTZRYCDCPTJ-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-(4-pentan-3-yl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound CCC(CC)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC(=CC=2)C2CC2)=C1 XQPSTZRYCDCPTJ-UHFFFAOYSA-N 0.000 claims 1
- PQMGWGOFVWECKF-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-(4-phenyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(=CC=2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1=CC=CC=C1 PQMGWGOFVWECKF-UHFFFAOYSA-N 0.000 claims 1
- VDXZIYAQWPGUPS-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-(4-propan-2-yl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound CC(C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC(=CC=2)C2CC2)=C1 VDXZIYAQWPGUPS-UHFFFAOYSA-N 0.000 claims 1
- INTURJDUCNJHIF-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-(4-pyridin-2-yl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(=CC=2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1=CC=CC=N1 INTURJDUCNJHIF-UHFFFAOYSA-N 0.000 claims 1
- LCKILEVPLUIPKT-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-(4-pyridin-3-yl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(=CC=2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1=CC=CN=C1 LCKILEVPLUIPKT-UHFFFAOYSA-N 0.000 claims 1
- UPJTWKYDWVAZPN-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-(4-pyridin-4-yl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(=CC=2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1=CC=NC=C1 UPJTWKYDWVAZPN-UHFFFAOYSA-N 0.000 claims 1
- PTGTWYUFALWBHL-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-(4-pyrimidin-5-yl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(=CC=2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1=CN=CN=C1 PTGTWYUFALWBHL-UHFFFAOYSA-N 0.000 claims 1
- GORYCFWKSUNYCW-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-[4-(1-pyridin-3-yloxypropan-2-yl)-1,2,4-triazol-3-yl]phenyl]pyridine-2-carboxamide Chemical compound C1=NN=C(C=2C=C(NC(=O)C=3N=CC=C(C=3)C=3C=NC(=CC=3)C3CC3)C=CC=2)N1C(C)COC1=CC=CN=C1 GORYCFWKSUNYCW-UHFFFAOYSA-N 0.000 claims 1
- NZVFKCPECCNKPL-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-[4-(2-phenylcyclopropyl)-1,2,4-triazol-3-yl]phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(=CC=2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1C1=CC=CC=C1 NZVFKCPECCNKPL-UHFFFAOYSA-N 0.000 claims 1
- LBACCMZFEURADW-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-[4-(3-hydroxybutan-2-yl)-1,2,4-triazol-3-yl]phenyl]pyridine-2-carboxamide Chemical compound CC(O)C(C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC(=CC=2)C2CC2)=C1 LBACCMZFEURADW-UHFFFAOYSA-N 0.000 claims 1
- LCXFAVSRNYTXBR-FQEVSTJZSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-[4-[(1s)-1-phenylethyl]-1,2,4-triazol-3-yl]phenyl]pyridine-2-carboxamide Chemical compound C1([C@H](C)N2C(=NN=C2)C=2C=C(NC(=O)C=3N=CC=C(C=3)C=3C=NC(=CC=3)C3CC3)C=CC=2)=CC=CC=C1 LCXFAVSRNYTXBR-FQEVSTJZSA-N 0.000 claims 1
- WHDVUGOEWSJVPZ-HSZRJFAPSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-[4-[(2r)-1-(2,6-dimethylphenoxy)propan-2-yl]-1,2,4-triazol-3-yl]phenyl]pyridine-2-carboxamide Chemical compound C([C@@H](C)N1C(=NN=C1)C=1C=C(NC(=O)C=2N=CC=C(C=2)C=2C=NC(=CC=2)C2CC2)C=CC=1)OC1=C(C)C=CC=C1C WHDVUGOEWSJVPZ-HSZRJFAPSA-N 0.000 claims 1
- VWUVSQBHGIBXRT-HNNXBMFYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-[4-[(2s)-1,1,1-trifluoropropan-2-yl]-1,2,4-triazol-3-yl]phenyl]pyridine-2-carboxamide Chemical compound FC(F)(F)[C@H](C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC(=CC=2)C2CC2)=C1 VWUVSQBHGIBXRT-HNNXBMFYSA-N 0.000 claims 1
- VRBJAMNRLJKDBF-KRWDZBQOSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-[4-[(2s)-1-methoxypropan-2-yl]-1,2,4-triazol-3-yl]phenyl]pyridine-2-carboxamide Chemical compound COC[C@H](C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC(=CC=2)C2CC2)=C1 VRBJAMNRLJKDBF-KRWDZBQOSA-N 0.000 claims 1
- TYFCBULBGOMMNM-SFHVURJKSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-[4-[(2s)-3,3-dimethylbutan-2-yl]-1,2,4-triazol-3-yl]phenyl]pyridine-2-carboxamide Chemical compound CC(C)(C)[C@H](C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC(=CC=2)C2CC2)=C1 TYFCBULBGOMMNM-SFHVURJKSA-N 0.000 claims 1
- FXNORAMBZTUWTL-SFHVURJKSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-[4-[(2s)-3-methylbutan-2-yl]-1,2,4-triazol-3-yl]phenyl]pyridine-2-carboxamide Chemical compound CC(C)[C@H](C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC(=CC=2)C2CC2)=C1 FXNORAMBZTUWTL-SFHVURJKSA-N 0.000 claims 1
- MFEGGOYIQWZCMZ-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[3-[4-[1-(2,2,2-trifluoroethoxy)propan-2-yl]-1,2,4-triazol-3-yl]phenyl]pyridine-2-carboxamide Chemical compound FC(F)(F)COCC(C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC(=CC=2)C2CC2)=C1 MFEGGOYIQWZCMZ-UHFFFAOYSA-N 0.000 claims 1
- HXYAABYWDBLUKS-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-5-methylpyridine-2-carboxamide Chemical compound CC1=CN=C(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)C=C1C(C=N1)=CC=C1C1CC1 HXYAABYWDBLUKS-UHFFFAOYSA-N 0.000 claims 1
- DEOJOKGSDYNDJQ-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-7,8-dimethylquinoline-2-carboxamide Chemical compound N=1C2=C(C)C(C)=CC=C2C(C=2C=NC(=CC=2)C2CC2)=CC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 DEOJOKGSDYNDJQ-UHFFFAOYSA-N 0.000 claims 1
- XDUJYPJVBLAJKJ-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(=CC=2)C2CC2)=CC=NC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 XDUJYPJVBLAJKJ-UHFFFAOYSA-N 0.000 claims 1
- WEQUSOAFGUTBRD-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]quinoline-2-carboxamide Chemical compound C=1C(C=2C=NC(=CC=2)C2CC2)=C2C=CC=CC2=NC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 WEQUSOAFGUTBRD-UHFFFAOYSA-N 0.000 claims 1
- IGQVVOYLYKCVIZ-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[6-(4-propan-2-yl-1,2,4-triazol-3-yl)pyridin-2-yl]pyridine-2-carboxamide Chemical compound CC(C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC(=CC=2)C2CC2)=N1 IGQVVOYLYKCVIZ-UHFFFAOYSA-N 0.000 claims 1
- JFLVKJCZAVMEAA-UHFFFAOYSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[6-[4-(1-pyrrolidin-1-ylpropan-2-yl)-1,2,4-triazol-3-yl]pyridin-2-yl]pyridine-2-carboxamide Chemical compound C1=NN=C(C=2N=C(NC(=O)C=3N=CC=C(C=3)C=3C=NC(=CC=3)C3CC3)C=CC=2)N1C(C)CN1CCCC1 JFLVKJCZAVMEAA-UHFFFAOYSA-N 0.000 claims 1
- GVUWMELDETZOSJ-CQSZACIVSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[6-[4-[(2r)-1,1,1-trifluoropropan-2-yl]-1,2,4-triazol-3-yl]pyridin-2-yl]pyridine-2-carboxamide Chemical compound FC(F)(F)[C@@H](C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC(=CC=2)C2CC2)=N1 GVUWMELDETZOSJ-CQSZACIVSA-N 0.000 claims 1
- MXYHSDMJCZGCDL-AAFJCEBUSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[6-[4-[(2r)-3-hydroxybutan-2-yl]-1,2,4-triazol-3-yl]pyridin-2-yl]pyridine-2-carboxamide Chemical compound CC(O)[C@@H](C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC(=CC=2)C2CC2)=N1 MXYHSDMJCZGCDL-AAFJCEBUSA-N 0.000 claims 1
- MXYHSDMJCZGCDL-JKSUJKDBSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[6-[4-[(2s,3r)-3-hydroxybutan-2-yl]-1,2,4-triazol-3-yl]pyridin-2-yl]pyridine-2-carboxamide Chemical compound C[C@@H](O)[C@H](C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC(=CC=2)C2CC2)=N1 MXYHSDMJCZGCDL-JKSUJKDBSA-N 0.000 claims 1
- MXYHSDMJCZGCDL-HOTGVXAUSA-N 4-(6-cyclopropylpyridin-3-yl)-n-[6-[4-[(2s,3s)-3-hydroxybutan-2-yl]-1,2,4-triazol-3-yl]pyridin-2-yl]pyridine-2-carboxamide Chemical compound C[C@H](O)[C@H](C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC(=CC=2)C2CC2)=N1 MXYHSDMJCZGCDL-HOTGVXAUSA-N 0.000 claims 1
- HTLNKQRNTPZZPF-UHFFFAOYSA-N 4-(6-tert-butylpyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C1=NC(C(C)(C)C)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 HTLNKQRNTPZZPF-UHFFFAOYSA-N 0.000 claims 1
- RHTBEYULLGYGIC-UHFFFAOYSA-N 4-(benzimidazol-1-yl)-n-[3-(3-cyclopropylimidazol-4-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(N2C3=CC=CC=C3N=C2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=CN=CN1C1CC1 RHTBEYULLGYGIC-UHFFFAOYSA-N 0.000 claims 1
- QYNIPIQABZPLGE-UHFFFAOYSA-N 4-(benzimidazol-1-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(N2C3=CC=CC=C3N=C2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 QYNIPIQABZPLGE-UHFFFAOYSA-N 0.000 claims 1
- HYJLJPAFUKVVIP-UHFFFAOYSA-N 4-(benzotriazol-1-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(N2C3=CC=CC=C3N=N2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 HYJLJPAFUKVVIP-UHFFFAOYSA-N 0.000 claims 1
- YMVHVUXATZHVLX-UHFFFAOYSA-N 4-[4-(cyclopropylsulfamoyl)phenyl]-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=CC(=CC=2)S(=O)(=O)NC2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 YMVHVUXATZHVLX-UHFFFAOYSA-N 0.000 claims 1
- PZHAJKQCOKCKIS-UHFFFAOYSA-N 4-[6-(cyclopropylamino)pyridin-3-yl]-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(NC3CC3)=CC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 PZHAJKQCOKCKIS-UHFFFAOYSA-N 0.000 claims 1
- JYWXDSFQZPJKKN-UHFFFAOYSA-N 4-[6-(cyclopropylmethyl)pyridin-3-yl]-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(CC3CC3)=CC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 JYWXDSFQZPJKKN-UHFFFAOYSA-N 0.000 claims 1
- JUVIUELFNWKSPW-UHFFFAOYSA-N 4-chloro-3-(4-cyclopropylimidazol-1-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]benzamide Chemical compound ClC1=CC=C(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)C=C1N(C=1)C=NC=1C1CC1 JUVIUELFNWKSPW-UHFFFAOYSA-N 0.000 claims 1
- FTZBXWOSEDDENS-UHFFFAOYSA-N 4-imidazo[1,2-a]pyridin-3-yl-n-[3-(4-methyl-1,2,4-triazol-3-yl)phenyl]pyridine-2-carboxamide Chemical compound CN1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2N3C=CC=CC3=NC=2)=C1 FTZBXWOSEDDENS-UHFFFAOYSA-N 0.000 claims 1
- DPIAFQOMVXIMSB-UHFFFAOYSA-N 4-pyridin-3-yl-n-[3-[4-(2,2,2-trifluoroethyl)-1,2,4-triazol-3-yl]phenyl]pyridine-2-carboxamide Chemical compound FC(F)(F)CN1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC=CC=2)=C1 DPIAFQOMVXIMSB-UHFFFAOYSA-N 0.000 claims 1
- LMBGTCSOQZKXEM-AWEZNQCLSA-N 4-pyridin-3-yl-n-[3-[4-[(2s)-1,1,1-trifluoropropan-2-yl]-1,2,4-triazol-3-yl]phenyl]pyridine-2-carboxamide Chemical compound FC(F)(F)[C@H](C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC=CC=2)=C1 LMBGTCSOQZKXEM-AWEZNQCLSA-N 0.000 claims 1
- FEBHPRFFYKZXST-UHFFFAOYSA-N 5-(2,5-difluorophenyl)-n-[3-(4-methyl-1,2,4-triazol-3-yl)phenyl]pyridine-3-carboxamide Chemical compound CN1C=NN=C1C1=CC=CC(NC(=O)C=2C=C(C=NC=2)C=2C(=CC=C(F)C=2)F)=C1 FEBHPRFFYKZXST-UHFFFAOYSA-N 0.000 claims 1
- HBAWHKLKYGOHCQ-UHFFFAOYSA-N 5-(4-cyclopropylimidazol-1-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-2-methylbenzamide Chemical compound CC1=CC=C(N2C=C(N=C2)C2CC2)C=C1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 HBAWHKLKYGOHCQ-UHFFFAOYSA-N 0.000 claims 1
- BORMTGVNZUGOQG-UHFFFAOYSA-N 5-(6-cyclopropylpyridin-3-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-2-fluorobenzamide Chemical compound FC1=CC=C(C=2C=NC(=CC=2)C2CC2)C=C1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 BORMTGVNZUGOQG-UHFFFAOYSA-N 0.000 claims 1
- JBEVHMTXTNJMDU-UHFFFAOYSA-N 6-(6-cyclopropylpyridin-3-yl)-n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]pyrimidine-4-carboxamide Chemical compound C=1C(C=2C=NC(=CC=2)C2CC2)=NC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 JBEVHMTXTNJMDU-UHFFFAOYSA-N 0.000 claims 1
- RNJXHBRLBNFYOM-UHFFFAOYSA-N 6-(6-cyclopropylpyridin-3-yl)-n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]pyridine-2-carboxamide Chemical compound C=1C=CC(C=2C=NC(=CC=2)C2CC2)=NC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 RNJXHBRLBNFYOM-UHFFFAOYSA-N 0.000 claims 1
- GUEXQAKJUQJTQH-UHFFFAOYSA-N 6-methyl-n-[3-(4-methyl-1,2,4-triazol-3-yl)phenyl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound N=1C(C)=CC(C=2C=NC=CC=2)=CC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C GUEXQAKJUQJTQH-UHFFFAOYSA-N 0.000 claims 1
- 229940077274 Alpha glucosidase inhibitor Drugs 0.000 claims 1
- 206010002383 Angina Pectoris Diseases 0.000 claims 1
- 206010006458 Bronchitis chronic Diseases 0.000 claims 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 1
- 102000001189 Cyclic Peptides Human genes 0.000 claims 1
- 108010069514 Cyclic Peptides Proteins 0.000 claims 1
- 208000032928 Dyslipidaemia Diseases 0.000 claims 1
- 206010014486 Elevated triglycerides Diseases 0.000 claims 1
- 206010014561 Emphysema Diseases 0.000 claims 1
- 208000007882 Gastritis Diseases 0.000 claims 1
- 208000005577 Gastroenteritis Diseases 0.000 claims 1
- 208000002705 Glucose Intolerance Diseases 0.000 claims 1
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 1
- JMBQKKAJIKAWKF-UHFFFAOYSA-N Glutethimide Chemical compound C=1C=CC=CC=1C1(CC)CCC(=O)NC1=O JMBQKKAJIKAWKF-UHFFFAOYSA-N 0.000 claims 1
- 229940122957 Histamine H2 receptor antagonist Drugs 0.000 claims 1
- 206010020772 Hypertension Diseases 0.000 claims 1
- 102000004877 Insulin Human genes 0.000 claims 1
- 108090001061 Insulin Proteins 0.000 claims 1
- 206010022562 Intermittent claudication Diseases 0.000 claims 1
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 1
- NPPQSCRMBWNHMW-UHFFFAOYSA-N Meprobamate Chemical compound NC(=O)OCC(C)(CCC)COC(N)=O NPPQSCRMBWNHMW-UHFFFAOYSA-N 0.000 claims 1
- 208000001145 Metabolic Syndrome Diseases 0.000 claims 1
- NLTWTTLCHYUSHG-UHFFFAOYSA-N O=C(Nc1cccc(n1)-c1nncn1C1CC1)c1cc(ccn1)-c1cccnc1.CS(=O)(=O)c1ccc(cc1)-c1ccnc(c1)C(=O)Nc1cccc(n1)-c1nncn1C1CC1 Chemical compound O=C(Nc1cccc(n1)-c1nncn1C1CC1)c1cc(ccn1)-c1cccnc1.CS(=O)(=O)c1ccc(cc1)-c1ccnc(c1)C(=O)Nc1cccc(n1)-c1nncn1C1CC1 NLTWTTLCHYUSHG-UHFFFAOYSA-N 0.000 claims 1
- 208000008589 Obesity Diseases 0.000 claims 1
- 206010033645 Pancreatitis Diseases 0.000 claims 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 claims 1
- 208000008469 Peptic Ulcer Diseases 0.000 claims 1
- 229940100389 Sulfonylurea Drugs 0.000 claims 1
- 239000004098 Tetracycline Substances 0.000 claims 1
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims 1
- 230000001154 acute effect Effects 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000000304 alkynyl group Chemical group 0.000 claims 1
- 239000003888 alpha glucosidase inhibitor Substances 0.000 claims 1
- 229940126575 aminoglycoside Drugs 0.000 claims 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 claims 1
- 229960000836 amitriptyline Drugs 0.000 claims 1
- 230000000202 analgesic effect Effects 0.000 claims 1
- 229940035676 analgesics Drugs 0.000 claims 1
- 229940069428 antacid Drugs 0.000 claims 1
- 239000003159 antacid agent Substances 0.000 claims 1
- 239000000730 antalgic agent Substances 0.000 claims 1
- 239000004004 anti-anginal agent Substances 0.000 claims 1
- 230000001430 anti-depressive effect Effects 0.000 claims 1
- 229940124345 antianginal agent Drugs 0.000 claims 1
- 239000003416 antiarrhythmic agent Substances 0.000 claims 1
- 239000003146 anticoagulant agent Substances 0.000 claims 1
- 229960004676 antithrombotic agent Drugs 0.000 claims 1
- 230000000949 anxiolytic effect Effects 0.000 claims 1
- 229940005530 anxiolytics Drugs 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 230000006793 arrhythmia Effects 0.000 claims 1
- 125000003710 aryl alkyl group Chemical group 0.000 claims 1
- 208000006673 asthma Diseases 0.000 claims 1
- 229940125717 barbiturate Drugs 0.000 claims 1
- 239000003782 beta lactam antibiotic agent Substances 0.000 claims 1
- 206010006451 bronchitis Diseases 0.000 claims 1
- 229940124630 bronchodilator Drugs 0.000 claims 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 claims 1
- 229960001058 bupropion Drugs 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- RNFNDJAIBTYOQL-UHFFFAOYSA-N chloral hydrate Chemical compound OC(O)C(Cl)(Cl)Cl RNFNDJAIBTYOQL-UHFFFAOYSA-N 0.000 claims 1
- 229960002327 chloral hydrate Drugs 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims 1
- 208000007451 chronic bronchitis Diseases 0.000 claims 1
- 229960001653 citalopram Drugs 0.000 claims 1
- 239000003246 corticosteroid Substances 0.000 claims 1
- 229940111134 coxibs Drugs 0.000 claims 1
- 125000001316 cycloalkyl alkyl group Chemical group 0.000 claims 1
- 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 claims 1
- 206010012601 diabetes mellitus Diseases 0.000 claims 1
- 208000010643 digestive system disease Diseases 0.000 claims 1
- 230000002526 effect on cardiovascular system Effects 0.000 claims 1
- 239000003792 electrolyte Substances 0.000 claims 1
- WSEQXVZVJXJVFP-FQEVSTJZSA-N escitalopram Chemical compound C1([C@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-FQEVSTJZSA-N 0.000 claims 1
- 229960004341 escitalopram Drugs 0.000 claims 1
- 229960002464 fluoxetine Drugs 0.000 claims 1
- 125000002541 furyl group Chemical group 0.000 claims 1
- 208000018685 gastrointestinal system disease Diseases 0.000 claims 1
- 229960002972 glutethimide Drugs 0.000 claims 1
- 125000004438 haloalkoxy group Chemical group 0.000 claims 1
- 125000004446 heteroarylalkyl group Chemical group 0.000 claims 1
- 125000004415 heterocyclylalkyl group Chemical group 0.000 claims 1
- MGXWVYUBJRZYPE-YUGYIWNOSA-N incretin Chemical class C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCC(N)=O)C(O)=O)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC=1C=CC(O)=CC=1)[C@@H](C)O)[C@@H](C)CC)C1=CC=C(O)C=C1 MGXWVYUBJRZYPE-YUGYIWNOSA-N 0.000 claims 1
- 239000000859 incretin Substances 0.000 claims 1
- 229940125396 insulin Drugs 0.000 claims 1
- 208000021156 intermittent vascular claudication Diseases 0.000 claims 1
- 208000028867 ischemia Diseases 0.000 claims 1
- 229940041028 lincosamides Drugs 0.000 claims 1
- 239000003120 macrolide antibiotic agent Substances 0.000 claims 1
- 229960004815 meprobamate Drugs 0.000 claims 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- LFVGNYGYHAHJOC-UHFFFAOYSA-N methyl n-[5-[2-[[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]carbamoyl]pyridin-4-yl]pyridin-2-yl]carbamate Chemical compound C1=NC(NC(=O)OC)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 LFVGNYGYHAHJOC-UHFFFAOYSA-N 0.000 claims 1
- 229960005181 morphine Drugs 0.000 claims 1
- 125000002757 morpholinyl group Chemical group 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- LOPBPYGKLPLRMH-UHFFFAOYSA-N n-[2-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-4-yl]-4-quinolin-3-ylpyridine-2-carboxamide Chemical compound C=1C(C=2C=C3C=CC=CC3=NC=2)=CC=NC=1C(=O)NC(C=1)=CC=NC=1C1=NN=CN1C1CC1 LOPBPYGKLPLRMH-UHFFFAOYSA-N 0.000 claims 1
- ZSIVCFPTLSXLTH-UHFFFAOYSA-N n-[3-(3-cyclopropylimidazol-4-yl)phenyl]-4-(6-cyclopropylpyridin-3-yl)pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(=CC=2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=CN=CN1C1CC1 ZSIVCFPTLSXLTH-UHFFFAOYSA-N 0.000 claims 1
- SOSKKYYLWDMZID-UHFFFAOYSA-N n-[3-(3-cyclopropylimidazol-4-yl)phenyl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound C=1C(C=2C=NC=CC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=CN=CN1C1CC1 SOSKKYYLWDMZID-UHFFFAOYSA-N 0.000 claims 1
- HKBWYBCOWCJXNN-UHFFFAOYSA-N n-[3-(3-cyclopropylimidazol-4-yl)phenyl]-4-quinolin-3-ylpyridine-2-carboxamide Chemical compound C=1C(C=2C=C3C=CC=CC3=NC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=CN=CN1C1CC1 HKBWYBCOWCJXNN-UHFFFAOYSA-N 0.000 claims 1
- LKRJATKOUOZZBH-UHFFFAOYSA-N n-[3-(4-but-2-ynyl-1,2,4-triazol-3-yl)phenyl]-4-(4-cyclopropylimidazol-1-yl)pyridine-2-carboxamide Chemical compound CC#CCN1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)N2C=C(N=C2)C2CC2)=C1 LKRJATKOUOZZBH-UHFFFAOYSA-N 0.000 claims 1
- YKZKDUCYZYVDOM-UHFFFAOYSA-N n-[3-(4-but-2-ynyl-1,2,4-triazol-3-yl)phenyl]-4-(6-cyclopropylpyridin-3-yl)pyridine-2-carboxamide Chemical compound CC#CCN1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC(=CC=2)C2CC2)=C1 YKZKDUCYZYVDOM-UHFFFAOYSA-N 0.000 claims 1
- ZYYCJXOQDWDLGN-UHFFFAOYSA-N n-[3-(4-butan-2-yl-1,2,4-triazol-3-yl)phenyl]-4-(6-cyclopropylpyridin-3-yl)pyridine-2-carboxamide Chemical compound CCC(C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC(=CC=2)C2CC2)=C1 ZYYCJXOQDWDLGN-UHFFFAOYSA-N 0.000 claims 1
- AOSNBVFWJSGSEZ-UHFFFAOYSA-N n-[3-(4-cyclobutyl-1,2,4-triazol-3-yl)phenyl]-4-(6-cyclopropylpyridin-3-yl)pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(=CC=2)C2CC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CCC1 AOSNBVFWJSGSEZ-UHFFFAOYSA-N 0.000 claims 1
- XXESGZXHEMVWTN-UHFFFAOYSA-N n-[3-(4-cyclobutyl-1,2,4-triazol-3-yl)phenyl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound C=1C(C=2C=NC=CC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CCC1 XXESGZXHEMVWTN-UHFFFAOYSA-N 0.000 claims 1
- PRGDOHNQSPEJFW-UHFFFAOYSA-N n-[3-(4-cyclopentyl-1,2,4-triazol-3-yl)phenyl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound C=1C(C=2C=NC=CC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CCCC1 PRGDOHNQSPEJFW-UHFFFAOYSA-N 0.000 claims 1
- UZIRCFXJGVIITM-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)-2-fluorophenyl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound C1=CC=C(C=2N(C=NN=2)C2CC2)C(F)=C1NC(=O)C(N=CC=1)=CC=1C1=CC=CN=C1 UZIRCFXJGVIITM-UHFFFAOYSA-N 0.000 claims 1
- JWVQUGPQDBPPKO-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)-4-fluorophenyl]-4-(6-ethylpyridin-3-yl)pyridine-2-carboxamide Chemical compound C1=NC(CC)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C(F)=CC=2)C=2N(C=NN=2)C2CC2)=C1 JWVQUGPQDBPPKO-UHFFFAOYSA-N 0.000 claims 1
- ZTXCAYUULVSBRA-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)-5-fluorophenyl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound C=1C(C=2N(C=NN=2)C2CC2)=CC(F)=CC=1NC(=O)C(N=CC=1)=CC=1C1=CC=CN=C1 ZTXCAYUULVSBRA-UHFFFAOYSA-N 0.000 claims 1
- KTYYSBXAPOFXOE-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(1,2,4-triazol-1-yl)pyridine-2-carboxamide Chemical compound C=1C(N2N=CN=C2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 KTYYSBXAPOFXOE-UHFFFAOYSA-N 0.000 claims 1
- NHZFWJSZZBCCBF-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(1,5-dimethylpyrazol-4-yl)pyridine-2-carboxamide Chemical compound C1=NN(C)C(C)=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 NHZFWJSZZBCCBF-UHFFFAOYSA-N 0.000 claims 1
- VZJUODFTXTXAHM-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(1,5-naphthyridin-3-yl)pyridine-2-carboxamide Chemical compound C=1C(C=2C=C3N=CC=CC3=NC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 VZJUODFTXTXAHM-UHFFFAOYSA-N 0.000 claims 1
- LCOUIACXSYVITE-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(1-methylpyrazol-4-yl)pyridine-2-carboxamide Chemical compound C1=NN(C)C=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 LCOUIACXSYVITE-UHFFFAOYSA-N 0.000 claims 1
- UDFRABUCTSRYSZ-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(1-propan-2-ylpyrrolo[3,2-b]pyridin-6-yl)pyridine-2-carboxamide Chemical compound C1=C2N(C(C)C)C=CC2=NC=C1C(C=1)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 UDFRABUCTSRYSZ-UHFFFAOYSA-N 0.000 claims 1
- JPMSYGDPZSKASB-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(1h-pyrrolo[2,3-b]pyridin-5-yl)pyridine-2-carboxamide Chemical compound C=1C(C=2C=C3C=CNC3=NC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 JPMSYGDPZSKASB-UHFFFAOYSA-N 0.000 claims 1
- BAWOUFGKEDURTL-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(1h-pyrrolo[3,2-b]pyridin-6-yl)pyridine-2-carboxamide Chemical compound C=1C(C=2C=C3NC=CC3=NC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 BAWOUFGKEDURTL-UHFFFAOYSA-N 0.000 claims 1
- ZLQWOOSBLKFTJK-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(2,3-dimethylimidazol-4-yl)pyridine-2-carboxamide Chemical compound CN1C(C)=NC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 ZLQWOOSBLKFTJK-UHFFFAOYSA-N 0.000 claims 1
- VDSUJHZINKZQFH-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(2,4-dimethoxypyrimidin-5-yl)pyridine-2-carboxamide Chemical compound COC1=NC(OC)=NC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 VDSUJHZINKZQFH-UHFFFAOYSA-N 0.000 claims 1
- YUAWMUJLIUFTFM-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(2-ethylpyrimidin-5-yl)pyridine-2-carboxamide Chemical compound C1=NC(CC)=NC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 YUAWMUJLIUFTFM-UHFFFAOYSA-N 0.000 claims 1
- OYJLIFQRHBFKCI-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(2-methoxypyridin-3-yl)pyridine-2-carboxamide Chemical compound COC1=NC=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 OYJLIFQRHBFKCI-UHFFFAOYSA-N 0.000 claims 1
- NVEXBDJERAOQLO-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(2-methoxypyrimidin-5-yl)pyridine-2-carboxamide Chemical compound C1=NC(OC)=NC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 NVEXBDJERAOQLO-UHFFFAOYSA-N 0.000 claims 1
- DGIZSTIXCJVKRY-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(2-methylimidazol-1-yl)pyridine-2-carboxamide Chemical compound CC1=NC=CN1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 DGIZSTIXCJVKRY-UHFFFAOYSA-N 0.000 claims 1
- LVYXHGMOOUZRJN-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(2-methylpyridin-3-yl)pyridine-2-carboxamide Chemical compound CC1=NC=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 LVYXHGMOOUZRJN-UHFFFAOYSA-N 0.000 claims 1
- LWFKSPOALPOTNO-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(2-methylsulfonylphenyl)pyridine-2-carboxamide Chemical compound CS(=O)(=O)C1=CC=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 LWFKSPOALPOTNO-UHFFFAOYSA-N 0.000 claims 1
- PIMFXZURRLLXDI-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(3-hydroxypiperidin-1-yl)pyridine-2-carboxamide Chemical compound C1C(O)CCCN1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 PIMFXZURRLLXDI-UHFFFAOYSA-N 0.000 claims 1
- VEOPYXPQHBXSEN-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(3-methyl-1,2,4-oxadiazol-5-yl)pyridine-2-carboxamide Chemical compound CC1=NOC(C=2C=C(N=CC=2)C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=N1 VEOPYXPQHBXSEN-UHFFFAOYSA-N 0.000 claims 1
- BXCHQPREKDUPMH-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(3-methyl-2-phenylimidazol-4-yl)pyridine-2-carboxamide Chemical compound CN1C(C=2C=C(N=CC=2)C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=CN=C1C1=CC=CC=C1 BXCHQPREKDUPMH-UHFFFAOYSA-N 0.000 claims 1
- TVRKVVFRMWPLMZ-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(3-methylimidazo[4,5-b]pyridin-6-yl)pyridine-2-carboxamide Chemical compound C=1N=C2N(C)C=NC2=CC=1C(C=1)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 TVRKVVFRMWPLMZ-UHFFFAOYSA-N 0.000 claims 1
- XKEAFANWKQKVSQ-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(3-methylimidazol-4-yl)pyridine-2-carboxamide Chemical compound CN1C=NC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 XKEAFANWKQKVSQ-UHFFFAOYSA-N 0.000 claims 1
- NADWNJBMCHMGNU-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(3-methylsulfonylphenyl)pyridine-2-carboxamide Chemical compound CS(=O)(=O)C1=CC=CC(C=2C=C(N=CC=2)C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 NADWNJBMCHMGNU-UHFFFAOYSA-N 0.000 claims 1
- MXTLRGXDTZELPI-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(4,5-dimethylimidazol-1-yl)pyridine-2-carboxamide Chemical compound CC1=C(C)N=CN1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 MXTLRGXDTZELPI-UHFFFAOYSA-N 0.000 claims 1
- QBFIQWYNEBNHJP-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(4-ethyl-3-oxopiperazin-1-yl)pyridine-2-carboxamide Chemical compound C1C(=O)N(CC)CCN1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 QBFIQWYNEBNHJP-UHFFFAOYSA-N 0.000 claims 1
- DGFYIMWJOWYRIQ-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(4-ethylimidazol-1-yl)pyridine-2-carboxamide Chemical compound C1=NC(CC)=CN1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 DGFYIMWJOWYRIQ-UHFFFAOYSA-N 0.000 claims 1
- ACDWSQREDGKAFT-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(4-ethylsulfonylphenyl)pyridine-2-carboxamide Chemical compound C1=CC(S(=O)(=O)CC)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 ACDWSQREDGKAFT-UHFFFAOYSA-N 0.000 claims 1
- YYJOZAHLGAHACX-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(4-methylimidazol-1-yl)pyridine-2-carboxamide Chemical compound C1=NC(C)=CN1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 YYJOZAHLGAHACX-UHFFFAOYSA-N 0.000 claims 1
- SJPPAAGARFZWNS-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(4-methylpyridin-3-yl)pyridine-2-carboxamide Chemical compound CC1=CC=NC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 SJPPAAGARFZWNS-UHFFFAOYSA-N 0.000 claims 1
- YBXKCRBRCJYTKT-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(4-methylsulfonylphenyl)pyridine-2-carboxamide Chemical compound C1=CC(S(=O)(=O)C)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 YBXKCRBRCJYTKT-UHFFFAOYSA-N 0.000 claims 1
- BZBRGMWUSRCAFW-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(4-methylsulfonylpiperazin-1-yl)pyridine-2-carboxamide Chemical compound C1CN(S(=O)(=O)C)CCN1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 BZBRGMWUSRCAFW-UHFFFAOYSA-N 0.000 claims 1
- YDDYRHXYGUNVIH-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(4-phenylimidazol-1-yl)pyridine-2-carboxamide Chemical compound C=1C(N2C=C(N=C2)C=2C=CC=CC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 YDDYRHXYGUNVIH-UHFFFAOYSA-N 0.000 claims 1
- NSBLRQRQYOPWCJ-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(4-propan-2-ylimidazol-1-yl)pyridine-2-carboxamide Chemical compound C1=NC(C(C)C)=CN1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 NSBLRQRQYOPWCJ-UHFFFAOYSA-N 0.000 claims 1
- ZZGMGULKPVQEMW-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(4-propan-2-ylsulfonylphenyl)pyridine-2-carboxamide Chemical compound C1=CC(S(=O)(=O)C(C)C)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 ZZGMGULKPVQEMW-UHFFFAOYSA-N 0.000 claims 1
- PQLJPIXGFQFBLQ-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(4-sulfamoylphenyl)pyridine-2-carboxamide Chemical compound C1=CC(S(=O)(=O)N)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 PQLJPIXGFQFBLQ-UHFFFAOYSA-N 0.000 claims 1
- MOEIRIXQBVJSDL-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(5,6,7,8-tetrahydro-1,6-naphthyridin-3-yl)pyridine-2-carboxamide Chemical compound C=1C(C=2C=C3CNCCC3=NC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 MOEIRIXQBVJSDL-UHFFFAOYSA-N 0.000 claims 1
- MGNBENZAYRLHPD-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(5,6-diethylpyridin-3-yl)pyridine-2-carboxamide Chemical compound N1=C(CC)C(CC)=CC(C=2C=C(N=CC=2)C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 MGNBENZAYRLHPD-UHFFFAOYSA-N 0.000 claims 1
- FPHNFBWCCUYIGD-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(5-ethylpyridin-3-yl)pyridine-2-carboxamide Chemical compound CCC1=CN=CC(C=2C=C(N=CC=2)C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 FPHNFBWCCUYIGD-UHFFFAOYSA-N 0.000 claims 1
- APNDFXWFNYAUPK-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(5-fluoropyridin-3-yl)pyridine-2-carboxamide Chemical compound FC1=CN=CC(C=2C=C(N=CC=2)C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 APNDFXWFNYAUPK-UHFFFAOYSA-N 0.000 claims 1
- RKWNPZYNQWHMNW-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(5-methoxypyridin-3-yl)pyridine-2-carboxamide Chemical compound COC1=CN=CC(C=2C=C(N=CC=2)C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 RKWNPZYNQWHMNW-UHFFFAOYSA-N 0.000 claims 1
- SDDOJDLRNYWTLO-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(6-ethyl-5-fluoropyridin-3-yl)pyridine-2-carboxamide Chemical compound C1=C(F)C(CC)=NC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 SDDOJDLRNYWTLO-UHFFFAOYSA-N 0.000 claims 1
- JVULQTVUMUMRAP-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(6-fluoro-5-methylpyridin-3-yl)pyridine-2-carboxamide Chemical compound N1=C(F)C(C)=CC(C=2C=C(N=CC=2)C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 JVULQTVUMUMRAP-UHFFFAOYSA-N 0.000 claims 1
- VEIPVPSITFJJBD-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(6-fluoropyridin-3-yl)pyridine-2-carboxamide Chemical compound C1=NC(F)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 VEIPVPSITFJJBD-UHFFFAOYSA-N 0.000 claims 1
- OCWFSCGCBTYILD-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(6-methoxypyridin-3-yl)pyridine-2-carboxamide Chemical compound C1=NC(OC)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 OCWFSCGCBTYILD-UHFFFAOYSA-N 0.000 claims 1
- YGHFHYNCRXPLDS-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(6-methoxyquinolin-3-yl)pyridine-2-carboxamide Chemical compound C=1C2=CC(OC)=CC=C2N=CC=1C(C=1)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 YGHFHYNCRXPLDS-UHFFFAOYSA-N 0.000 claims 1
- BTZVLKJJVVPPJV-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(6-methylpyridin-3-yl)pyridine-2-carboxamide Chemical compound C1=NC(C)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 BTZVLKJJVVPPJV-UHFFFAOYSA-N 0.000 claims 1
- ULAMEPHYFLWXOF-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(6-methylsulfanylpyridin-3-yl)pyridine-2-carboxamide Chemical compound C1=NC(SC)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 ULAMEPHYFLWXOF-UHFFFAOYSA-N 0.000 claims 1
- LOXGOQPJODPIND-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(6-oxo-1h-pyridin-3-yl)pyridine-2-carboxamide Chemical compound C1=NC(O)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 LOXGOQPJODPIND-UHFFFAOYSA-N 0.000 claims 1
- ROXITARWDFOLPR-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(6-propan-2-yloxypyridin-3-yl)pyridine-2-carboxamide Chemical compound C1=NC(OC(C)C)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 ROXITARWDFOLPR-UHFFFAOYSA-N 0.000 claims 1
- KKPWBZLVANVAJH-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(6-propan-2-ylpyridin-3-yl)pyridine-2-carboxamide Chemical compound C1=NC(C(C)C)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 KKPWBZLVANVAJH-UHFFFAOYSA-N 0.000 claims 1
- QDYWHKKQBLXWBA-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(6-propylpyridin-3-yl)pyridine-2-carboxamide Chemical compound C1=NC(CCC)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 QDYWHKKQBLXWBA-UHFFFAOYSA-N 0.000 claims 1
- PTMFZWYUDDQMDS-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-(6-pyrrolidin-1-ylpyridin-3-yl)pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(=CC=2)N2CCCC2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 PTMFZWYUDDQMDS-UHFFFAOYSA-N 0.000 claims 1
- FMODEHMEPLTKHQ-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[1-(2,2,2-trifluoroethyl)pyrrolo[3,2-b]pyridin-6-yl]pyridine-2-carboxamide Chemical compound C1=C2N(CC(F)(F)F)C=CC2=NC=C1C(C=1)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 FMODEHMEPLTKHQ-UHFFFAOYSA-N 0.000 claims 1
- CGFCTORCZQUIRW-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[4-(1,1,2,2,2-pentafluoroethyl)imidazol-1-yl]pyridine-2-carboxamide Chemical compound C1=NC(C(F)(F)C(F)(F)F)=CN1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 CGFCTORCZQUIRW-UHFFFAOYSA-N 0.000 claims 1
- IMIYTEJJZKVFNR-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[4-(2,2,2-trifluoro-1-hydroxyethyl)imidazol-1-yl]pyridine-2-carboxamide Chemical compound C1=NC(C(O)C(F)(F)F)=CN1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 IMIYTEJJZKVFNR-UHFFFAOYSA-N 0.000 claims 1
- MLENIDSWDIOPDU-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[4-(2-oxoimidazolidin-1-yl)phenyl]pyridine-2-carboxamide Chemical compound C=1C(C=2C=CC(=CC=2)N2C(NCC2)=O)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 MLENIDSWDIOPDU-UHFFFAOYSA-N 0.000 claims 1
- WINSJHXUMGUFNC-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[4-(methylsulfamoyl)phenyl]pyridine-2-carboxamide Chemical compound C1=CC(S(=O)(=O)NC)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 WINSJHXUMGUFNC-UHFFFAOYSA-N 0.000 claims 1
- MCFXHZHKKLHALL-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[4-(propan-2-ylsulfamoyl)phenyl]pyridine-2-carboxamide Chemical compound C1=CC(S(=O)(=O)NC(C)C)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 MCFXHZHKKLHALL-UHFFFAOYSA-N 0.000 claims 1
- MKBOTAVPIZHXSY-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[4-(trifluoromethyl)-4,5,6,7-tetrahydroimidazo[4,5-c]pyridin-1-yl]pyridine-2-carboxamide Chemical compound FC(F)(F)C1NCCC2=C1N=CN2C(C=1)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 MKBOTAVPIZHXSY-UHFFFAOYSA-N 0.000 claims 1
- IQCMDAGESBTEGG-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[4-(trifluoromethyl)imidazol-1-yl]pyridine-2-carboxamide Chemical compound C1=NC(C(F)(F)F)=CN1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 IQCMDAGESBTEGG-UHFFFAOYSA-N 0.000 claims 1
- AVDQYQSCVJHEGI-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[5-(1-hydroxyethyl)-1,3,4-oxadiazol-2-yl]pyridine-2-carboxamide Chemical compound O1C(C(O)C)=NN=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 AVDQYQSCVJHEGI-UHFFFAOYSA-N 0.000 claims 1
- PDPRUTBJSBYJMK-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[5-(trifluoromethyl)pyridin-3-yl]pyridine-2-carboxamide Chemical compound FC(F)(F)C1=CN=CC(C=2C=C(N=CC=2)C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 PDPRUTBJSBYJMK-UHFFFAOYSA-N 0.000 claims 1
- OPARQLUIZUMIQR-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[5-methyl-4-(trifluoromethyl)-6,7-dihydro-4h-imidazo[4,5-c]pyridin-1-yl]pyridine-2-carboxamide Chemical compound FC(F)(F)C1N(C)CCC2=C1N=CN2C(C=1)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 OPARQLUIZUMIQR-UHFFFAOYSA-N 0.000 claims 1
- PKKTWVWHPTYOAW-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[6-(1-methyl-2-oxopyrrolidin-3-yl)pyridin-3-yl]pyridine-2-carboxamide Chemical compound O=C1N(C)CCC1C1=CC=C(C=2C=C(N=CC=2)C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)C=N1 PKKTWVWHPTYOAW-UHFFFAOYSA-N 0.000 claims 1
- CDSVDQUEAQEVNU-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[6-(2,2,2-trifluoroethoxy)pyridin-3-yl]pyridine-2-carboxamide Chemical compound C1=NC(OCC(F)(F)F)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 CDSVDQUEAQEVNU-UHFFFAOYSA-N 0.000 claims 1
- WLBOLZRNHWXDAF-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[6-(2,2,2-trifluoroethyl)-7,8-dihydro-5h-1,6-naphthyridin-3-yl]pyridine-2-carboxamide Chemical compound C1=C2CN(CC(F)(F)F)CCC2=NC=C1C(C=1)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 WLBOLZRNHWXDAF-UHFFFAOYSA-N 0.000 claims 1
- KWOXVXDOTCOBNJ-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[6-(2,2,2-trifluoroethyl)pyridin-3-yl]pyridine-2-carboxamide Chemical compound C1=NC(CC(F)(F)F)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 KWOXVXDOTCOBNJ-UHFFFAOYSA-N 0.000 claims 1
- HHYPKBOJJRBKOA-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[6-(2,2-dimethylpropyl)pyridin-3-yl]pyridine-2-carboxamide Chemical compound C1=NC(CC(C)(C)C)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 HHYPKBOJJRBKOA-UHFFFAOYSA-N 0.000 claims 1
- GXYQTJPYHJWXBU-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]pyridine-2-carboxamide Chemical compound C1=NC(C(C)(O)C)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 GXYQTJPYHJWXBU-UHFFFAOYSA-N 0.000 claims 1
- DVJLXJHDFJUWIS-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[6-(2-methoxyethylamino)pyridin-3-yl]pyridine-2-carboxamide Chemical compound C1=NC(NCCOC)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 DVJLXJHDFJUWIS-UHFFFAOYSA-N 0.000 claims 1
- QJBICXBKPIAIDN-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[6-(2-methylpropylsulfanyl)pyridin-3-yl]pyridine-2-carboxamide Chemical compound C1=NC(SCC(C)C)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 QJBICXBKPIAIDN-UHFFFAOYSA-N 0.000 claims 1
- KQWPJCHHUHXQIW-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[6-(dimethylamino)pyridin-3-yl]pyridine-2-carboxamide Chemical compound C1=NC(N(C)C)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 KQWPJCHHUHXQIW-UHFFFAOYSA-N 0.000 claims 1
- WIJIZIFAAWYWSS-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[6-(ethylamino)pyridin-3-yl]pyridine-2-carboxamide Chemical compound C1=NC(NCC)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 WIJIZIFAAWYWSS-UHFFFAOYSA-N 0.000 claims 1
- CCAJGWCPXSPDAF-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-[6-(trifluoromethyl)pyridin-3-yl]pyridine-2-carboxamide Chemical compound C1=NC(C(F)(F)F)=CC=C1C1=CC=NC(C(=O)NC=2C=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 CCAJGWCPXSPDAF-UHFFFAOYSA-N 0.000 claims 1
- PSIMXSRMFLQFGJ-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-furo[3,2-b]pyridin-6-ylpyridine-2-carboxamide Chemical compound C=1C(C=2C=C3OC=CC3=NC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 PSIMXSRMFLQFGJ-UHFFFAOYSA-N 0.000 claims 1
- GQHFMRSHSWGKLA-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-imidazo[1,2-a]pyridin-3-ylpyridine-2-carboxamide Chemical compound C=1C(C=2N3C=CC=CC3=NC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 GQHFMRSHSWGKLA-UHFFFAOYSA-N 0.000 claims 1
- LXVWJNKBAUBAPV-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-imidazo[2,1-b][1,3,4]thiadiazol-5-ylpyridine-2-carboxamide Chemical compound C=1C(C=2N3N=CSC3=NC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 LXVWJNKBAUBAPV-UHFFFAOYSA-N 0.000 claims 1
- WFGZWQJMZCICOK-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-imidazo[4,5-b]pyridin-1-ylpyridine-2-carboxamide Chemical compound C=1C(N2C3=CC=CN=C3N=C2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 WFGZWQJMZCICOK-UHFFFAOYSA-N 0.000 claims 1
- BSAGZPRHCTWICK-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-imidazo[4,5-b]pyridin-3-ylpyridine-2-carboxamide Chemical compound C=1C(N2C3=NC=CC=C3N=C2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 BSAGZPRHCTWICK-UHFFFAOYSA-N 0.000 claims 1
- AWTXUPWCHCJCQT-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-imidazo[4,5-c]pyridin-1-ylpyridine-2-carboxamide Chemical compound C=1C(N2C3=CC=NC=C3N=C2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 AWTXUPWCHCJCQT-UHFFFAOYSA-N 0.000 claims 1
- SSBHVJGIWMTWBB-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-imidazol-1-ylpyridine-2-carboxamide Chemical compound C=1C(N2C=NC=C2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 SSBHVJGIWMTWBB-UHFFFAOYSA-N 0.000 claims 1
- CLPUKMIIBZWEIT-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-isoquinolin-4-ylpyridine-2-carboxamide Chemical compound C=1C(C=2C3=CC=CC=C3C=NC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 CLPUKMIIBZWEIT-UHFFFAOYSA-N 0.000 claims 1
- FDENWWSRCRMZTK-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-phenylpyridine-2-carboxamide Chemical compound C=1C(C=2C=CC=CC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 FDENWWSRCRMZTK-UHFFFAOYSA-N 0.000 claims 1
- QSLDECRRWPIQFB-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-pyrazin-2-ylpyridine-2-carboxamide Chemical compound C=1C(C=2N=CC=NC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 QSLDECRRWPIQFB-UHFFFAOYSA-N 0.000 claims 1
- WZOKIKOXWFAJPO-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-pyridin-3-yl-6-(trifluoromethyl)pyridine-2-carboxamide Chemical compound N=1C(C(F)(F)F)=CC(C=2C=NC=CC=2)=CC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 WZOKIKOXWFAJPO-UHFFFAOYSA-N 0.000 claims 1
- SZZKJPNBENKCOL-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound C=1C(C=2C=NC=CC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 SZZKJPNBENKCOL-UHFFFAOYSA-N 0.000 claims 1
- CEUXPAJIHAMDHP-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-pyridin-3-ylquinoline-2-carboxamide Chemical compound C=1C(C=2C=NC=CC=2)=C2C=CC=CC2=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 CEUXPAJIHAMDHP-UHFFFAOYSA-N 0.000 claims 1
- UWSIKOMZQIASHE-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-quinolin-3-yl-6-(trifluoromethyl)pyridine-2-carboxamide Chemical compound N=1C(C(F)(F)F)=CC(C=2C=C3C=CC=CC3=NC=2)=CC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 UWSIKOMZQIASHE-UHFFFAOYSA-N 0.000 claims 1
- DCOLXDBAPJCAFC-UHFFFAOYSA-N n-[3-(4-cyclopropyl-1,2,4-triazol-3-yl)phenyl]-4-quinolin-3-ylpyridine-2-carboxamide Chemical compound C=1C(C=2C=C3C=CC=CC3=NC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CC1 DCOLXDBAPJCAFC-UHFFFAOYSA-N 0.000 claims 1
- SRXPGSUMSMKMPL-UHFFFAOYSA-N n-[3-(4-methyl-1,2,4-triazol-3-yl)phenyl]-2-oxo-4-phenyl-1h-pyrimidine-6-carboxamide Chemical compound CN1C=NN=C1C1=CC=CC(NC(=O)C=2N=C(O)N=C(C=2)C=2C=CC=CC=2)=C1 SRXPGSUMSMKMPL-UHFFFAOYSA-N 0.000 claims 1
- WYJWCEANLTYWTF-UHFFFAOYSA-N n-[3-(4-methyl-1,2,4-triazol-3-yl)phenyl]-2-phenylpyridine-4-carboxamide Chemical compound CN1C=NN=C1C1=CC=CC(NC(=O)C=2C=C(N=CC=2)C=2C=CC=CC=2)=C1 WYJWCEANLTYWTF-UHFFFAOYSA-N 0.000 claims 1
- WOMAYAFDTFYGQZ-UHFFFAOYSA-N n-[3-(4-methyl-1,2,4-triazol-3-yl)phenyl]-4-(3-oxopiperazin-1-yl)pyridine-2-carboxamide Chemical compound CN1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)N2CC(=O)NCC2)=C1 WOMAYAFDTFYGQZ-UHFFFAOYSA-N 0.000 claims 1
- PKYSWTANUVYWLS-UHFFFAOYSA-N n-[3-(4-methyl-1,2,4-triazol-3-yl)phenyl]-4-morpholin-4-ylpyridine-2-carboxamide Chemical compound CN1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)N2CCOCC2)=C1 PKYSWTANUVYWLS-UHFFFAOYSA-N 0.000 claims 1
- PFSJJBKGIXSPHS-UHFFFAOYSA-N n-[3-(4-methyl-1,2,4-triazol-3-yl)phenyl]-4-phenylpyridine-2-carboxamide Chemical compound CN1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=CC=CC=2)=C1 PFSJJBKGIXSPHS-UHFFFAOYSA-N 0.000 claims 1
- JYQLUKILLCAADR-UHFFFAOYSA-N n-[3-(4-methyl-1,2,4-triazol-3-yl)phenyl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound CN1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC=CC=2)=C1 JYQLUKILLCAADR-UHFFFAOYSA-N 0.000 claims 1
- IAFYRYKGLRMXEU-UHFFFAOYSA-N n-[3-(4-methyl-1,2,4-triazol-3-yl)phenyl]-5-phenylpyridine-3-carboxamide Chemical compound CN1C=NN=C1C1=CC=CC(NC(=O)C=2C=C(C=NC=2)C=2C=CC=CC=2)=C1 IAFYRYKGLRMXEU-UHFFFAOYSA-N 0.000 claims 1
- ZSROJHFZIVYSMI-UHFFFAOYSA-N n-[3-(4-methyl-1,2,4-triazol-3-yl)phenyl]-5-pyridin-3-ylpyridine-3-carboxamide Chemical compound CN1C=NN=C1C1=CC=CC(NC(=O)C=2C=C(C=NC=2)C=2C=NC=CC=2)=C1 ZSROJHFZIVYSMI-UHFFFAOYSA-N 0.000 claims 1
- MKJSHVZGTNLRAM-UHFFFAOYSA-N n-[3-(4-methyl-1,2,4-triazol-3-yl)phenyl]-6-phenylpyridine-2-carboxamide Chemical compound CN1C=NN=C1C1=CC=CC(NC(=O)C=2N=C(C=CC=2)C=2C=CC=CC=2)=C1 MKJSHVZGTNLRAM-UHFFFAOYSA-N 0.000 claims 1
- XZHNORWGXWLOLL-UHFFFAOYSA-N n-[3-(4-methyl-1,2,4-triazol-3-yl)phenyl]-6-pyridin-3-ylpyridine-2-carboxamide Chemical compound CN1C=NN=C1C1=CC=CC(NC(=O)C=2N=C(C=CC=2)C=2C=NC=CC=2)=C1 XZHNORWGXWLOLL-UHFFFAOYSA-N 0.000 claims 1
- ZTVWAKNJQNHSPQ-UHFFFAOYSA-N n-[3-(4-methyl-1,2,4-triazol-3-yl)phenyl]-6-quinolin-6-ylpyridine-2-carboxamide Chemical compound CN1C=NN=C1C1=CC=CC(NC(=O)C=2N=C(C=CC=2)C=2C=C3C=CC=NC3=CC=2)=C1 ZTVWAKNJQNHSPQ-UHFFFAOYSA-N 0.000 claims 1
- YOZDNZWJLCHYAF-UHFFFAOYSA-N n-[3-(4-propan-2-yl-1,2,4-triazol-3-yl)phenyl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound CC(C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC=CC=2)=C1 YOZDNZWJLCHYAF-UHFFFAOYSA-N 0.000 claims 1
- ZWGFJPOMULUDJA-UHFFFAOYSA-N n-[3-[4-(2-acetamidoethyl)-1,2,4-triazol-3-yl]phenyl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound CC(=O)NCCN1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC=CC=2)=C1 ZWGFJPOMULUDJA-UHFFFAOYSA-N 0.000 claims 1
- QJDGQFRJJWEABP-UHFFFAOYSA-N n-[3-[4-(3-amino-3-oxopropyl)-1,2,4-triazol-3-yl]phenyl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound NC(=O)CCN1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC=CC=2)=C1 QJDGQFRJJWEABP-UHFFFAOYSA-N 0.000 claims 1
- MMLSXESZMOJTSL-UHFFFAOYSA-N n-[3-[4-(cyclopropylmethyl)-1,2,4-triazol-3-yl]phenyl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound C=1C(C=2C=NC=CC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1CC1CC1 MMLSXESZMOJTSL-UHFFFAOYSA-N 0.000 claims 1
- CJMHCJTZSYOBPU-UHFFFAOYSA-N n-[3-[4-(oxan-4-yl)-1,2,4-triazol-3-yl]phenyl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound C=1C(C=2C=NC=CC=2)=CC=NC=1C(=O)NC(C=1)=CC=CC=1C1=NN=CN1C1CCOCC1 CJMHCJTZSYOBPU-UHFFFAOYSA-N 0.000 claims 1
- CSCUXDGJDWIJCL-UHFFFAOYSA-N n-[3-[4-[(1-hydroxycyclopropyl)methyl]-1,2,4-triazol-3-yl]phenyl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound C1=NN=C(C=2C=C(NC(=O)C=3N=CC=C(C=3)C=3C=NC=CC=3)C=CC=2)N1CC1(O)CC1 CSCUXDGJDWIJCL-UHFFFAOYSA-N 0.000 claims 1
- BVOBNMVXPBIOMV-KRWDZBQOSA-N n-[3-[4-[(1s)-1-cyclopropylethyl]-1,2,4-triazol-3-yl]phenyl]-4-(6-cyclopropylpyridin-3-yl)pyridine-2-carboxamide Chemical compound C1([C@H](C)N2C(=NN=C2)C=2C=C(NC(=O)C=3N=CC=C(C=3)C=3C=NC(=CC=3)C3CC3)C=CC=2)CC1 BVOBNMVXPBIOMV-KRWDZBQOSA-N 0.000 claims 1
- DLNQWRWREPCCDJ-BTYIYWSLSA-N n-[3-[4-[(1s,2s)-2-methylcyclopropyl]-1,2,4-triazol-3-yl]phenyl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound C[C@H]1C[C@@H]1N1C(C=2C=C(NC(=O)C=3N=CC=C(C=3)C=3C=NC=CC=3)C=CC=2)=NN=C1 DLNQWRWREPCCDJ-BTYIYWSLSA-N 0.000 claims 1
- QSBUJZCNLVMSKA-OAHLLOKOSA-N n-[3-[4-[(2r)-1-hydroxypropan-2-yl]-1,2,4-triazol-3-yl]phenyl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound OC[C@@H](C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC=CC=2)=C1 QSBUJZCNLVMSKA-OAHLLOKOSA-N 0.000 claims 1
- LBFWQZDYRKJISZ-OAHLLOKOSA-N n-[3-[4-[(2r)-2-hydroxypropyl]-1,2,4-triazol-3-yl]phenyl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound C[C@@H](O)CN1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC=CC=2)=C1 LBFWQZDYRKJISZ-OAHLLOKOSA-N 0.000 claims 1
- QSBUJZCNLVMSKA-HNNXBMFYSA-N n-[3-[4-[(2s)-1-hydroxypropan-2-yl]-1,2,4-triazol-3-yl]phenyl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound OC[C@H](C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC=CC=2)=C1 QSBUJZCNLVMSKA-HNNXBMFYSA-N 0.000 claims 1
- LBFWQZDYRKJISZ-HNNXBMFYSA-N n-[3-[4-[(2s)-2-hydroxypropyl]-1,2,4-triazol-3-yl]phenyl]-4-pyridin-3-ylpyridine-2-carboxamide Chemical compound C[C@H](O)CN1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC=CC=2)=C1 LBFWQZDYRKJISZ-HNNXBMFYSA-N 0.000 claims 1
- ZYYCJXOQDWDLGN-KRWDZBQOSA-N n-[3-[4-[(2s)-butan-2-yl]-1,2,4-triazol-3-yl]phenyl]-4-(6-cyclopropylpyridin-3-yl)pyridine-2-carboxamide Chemical compound CC[C@H](C)N1C=NN=C1C1=CC=CC(NC(=O)C=2N=CC=C(C=2)C=2C=NC(=CC=2)C2CC2)=C1 ZYYCJXOQDWDLGN-KRWDZBQOSA-N 0.000 claims 1
- SJJYGTVUWDVNDY-UHFFFAOYSA-N n-[6-(3-cyclopropylimidazol-4-yl)pyridin-2-yl]-4-(4,5-dimethylimidazol-1-yl)pyridine-2-carboxamide Chemical compound CC1=C(C)N=CN1C1=CC=NC(C(=O)NC=2N=C(C=CC=2)C=2N(C=NC=2)C2CC2)=C1 SJJYGTVUWDVNDY-UHFFFAOYSA-N 0.000 claims 1
- JOAGLBRFMWKWAY-UHFFFAOYSA-N n-[6-(3-cyclopropylimidazol-4-yl)pyridin-2-yl]-4-(6-cyclopropylpyridin-3-yl)pyridine-2-carboxamide Chemical compound C=1C(C=2C=NC(=CC=2)C2CC2)=CC=NC=1C(=O)NC(N=1)=CC=CC=1C1=CN=CN1C1CC1 JOAGLBRFMWKWAY-UHFFFAOYSA-N 0.000 claims 1
- BZSPITOKXNYMIL-UHFFFAOYSA-N n-[6-(3-cyclopropylimidazol-4-yl)pyridin-2-yl]-4-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]pyridine-2-carboxamide Chemical compound C1=NC(C(C)(O)C)=CC=C1C1=CC=NC(C(=O)NC=2N=C(C=CC=2)C=2N(C=NC=2)C2CC2)=C1 BZSPITOKXNYMIL-UHFFFAOYSA-N 0.000 claims 1
- QSBJEMJHIREIDF-UHFFFAOYSA-N n-[6-(3-cyclopropylimidazol-4-yl)pyridin-2-yl]-4-quinolin-3-ylpyridine-2-carboxamide Chemical compound C=1C(C=2C=C3C=CC=CC3=NC=2)=CC=NC=1C(=O)NC(N=1)=CC=CC=1C1=CN=CN1C1CC1 QSBJEMJHIREIDF-UHFFFAOYSA-N 0.000 claims 1
- LTLQDJLAQRIRKR-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-3-(1,5-naphthyridin-3-yl)benzamide Chemical compound C=1C=CC(C=2C=C3N=CC=CC3=NC=2)=CC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 LTLQDJLAQRIRKR-UHFFFAOYSA-N 0.000 claims 1
- FCPPUDFGPFUSRX-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-3-(4,5,6,7-tetrahydrobenzimidazol-1-yl)benzamide Chemical compound C=1C=CC(N2C=3CCCCC=3N=C2)=CC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 FCPPUDFGPFUSRX-UHFFFAOYSA-N 0.000 claims 1
- CUPFKQJBPJLHMP-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-3-(4,5-dimethylimidazol-1-yl)benzamide Chemical compound CC1=C(C)N=CN1C1=CC=CC(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 CUPFKQJBPJLHMP-UHFFFAOYSA-N 0.000 claims 1
- MMQIDSMZFJLWGS-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-3-(4-propan-2-ylimidazol-1-yl)benzamide Chemical compound C1=NC(C(C)C)=CN1C1=CC=CC(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 MMQIDSMZFJLWGS-UHFFFAOYSA-N 0.000 claims 1
- HHNJQIRNAMVSNX-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-3-[4-(2,2,2-trifluoro-1-hydroxyethyl)imidazol-1-yl]benzamide Chemical compound C1=NC(C(O)C(F)(F)F)=CN1C1=CC=CC(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 HHNJQIRNAMVSNX-UHFFFAOYSA-N 0.000 claims 1
- AIYXIYDKEYUQDS-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-3-[4-(2,2,2-trifluoro-1-methoxyethyl)imidazol-1-yl]benzamide Chemical compound C1=NC(C(OC)C(F)(F)F)=CN1C1=CC=CC(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 AIYXIYDKEYUQDS-UHFFFAOYSA-N 0.000 claims 1
- UOCPJOQEMBOMOO-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-3-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]benzamide Chemical compound C1=NC(C(C)(O)C)=CC=C1C1=CC=CC(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 UOCPJOQEMBOMOO-UHFFFAOYSA-N 0.000 claims 1
- BHKDDULOOMQUMP-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-3-pyridin-3-ylbenzamide Chemical compound C=1C=CC(C=2C=NC=CC=2)=CC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 BHKDDULOOMQUMP-UHFFFAOYSA-N 0.000 claims 1
- HXMHZJPPAYHFEW-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-3-quinolin-3-ylbenzamide Chemical compound C=1C=CC(C=2C=C3C=CC=CC3=NC=2)=CC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 HXMHZJPPAYHFEW-UHFFFAOYSA-N 0.000 claims 1
- PHLIEZXYUULPHF-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-4-(3-hydroxypiperidin-1-yl)pyridine-2-carboxamide Chemical compound C1C(O)CCCN1C1=CC=NC(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 PHLIEZXYUULPHF-UHFFFAOYSA-N 0.000 claims 1
- YZPHWCAWCRTXRI-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-4-(4,5,6,7-tetrahydrobenzimidazol-1-yl)pyridine-2-carboxamide Chemical compound C=1C(N2C=3CCCCC=3N=C2)=CC=NC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 YZPHWCAWCRTXRI-UHFFFAOYSA-N 0.000 claims 1
- XGTKHQCAYAXHKY-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-4-(4,5-dimethylimidazol-1-yl)pyridine-2-carboxamide Chemical compound CC1=C(C)N=CN1C1=CC=NC(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 XGTKHQCAYAXHKY-UHFFFAOYSA-N 0.000 claims 1
- KJARSCYCCLZWRM-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-4-(4-ethyl-3-oxopiperazin-1-yl)pyridine-2-carboxamide Chemical compound C1C(=O)N(CC)CCN1C1=CC=NC(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 KJARSCYCCLZWRM-UHFFFAOYSA-N 0.000 claims 1
- VQPJSWDNPZOEKX-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-4-(4-methylimidazol-1-yl)pyridine-2-carboxamide Chemical compound C1=NC(C)=CN1C1=CC=NC(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 VQPJSWDNPZOEKX-UHFFFAOYSA-N 0.000 claims 1
- LNYQTEWKYOBOOO-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-4-(4-phenylimidazol-1-yl)pyridine-2-carboxamide Chemical compound C=1C(N2C=C(N=C2)C=2C=CC=CC=2)=CC=NC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 LNYQTEWKYOBOOO-UHFFFAOYSA-N 0.000 claims 1
- GFRXYBKWDFPKGO-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-4-(4-propan-2-ylimidazol-1-yl)pyridine-2-carboxamide Chemical compound C1=NC(C(C)C)=CN1C1=CC=NC(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 GFRXYBKWDFPKGO-UHFFFAOYSA-N 0.000 claims 1
- RGPKITGJSDQXKA-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-4-[4-(1,1,2,2,2-pentafluoroethyl)imidazol-1-yl]pyridine-2-carboxamide Chemical compound C1=NC(C(F)(F)C(F)(F)F)=CN1C1=CC=NC(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 RGPKITGJSDQXKA-UHFFFAOYSA-N 0.000 claims 1
- FNMVLSJKVZPRTF-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-4-[4-(2,2,2-trifluoro-1-hydroxyethyl)imidazol-1-yl]pyridine-2-carboxamide Chemical compound C1=NC(C(O)C(F)(F)F)=CN1C1=CC=NC(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 FNMVLSJKVZPRTF-UHFFFAOYSA-N 0.000 claims 1
- JZFLHCHLJVHJON-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-4-[4-(methylsulfamoyl)phenyl]pyridine-2-carboxamide Chemical compound C1=CC(S(=O)(=O)NC)=CC=C1C1=CC=NC(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 JZFLHCHLJVHJON-UHFFFAOYSA-N 0.000 claims 1
- FFOVSBHCQMETLA-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-4-[4-(trifluoromethyl)-4,5,6,7-tetrahydroimidazo[4,5-c]pyridin-1-yl]pyridine-2-carboxamide Chemical compound FC(F)(F)C1NCCC2=C1N=CN2C(C=1)=CC=NC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 FFOVSBHCQMETLA-UHFFFAOYSA-N 0.000 claims 1
- HLVLRZLEIYSGOP-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-4-[4-(trifluoromethyl)imidazol-1-yl]pyridine-2-carboxamide Chemical compound C1=NC(C(F)(F)F)=CN1C1=CC=NC(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 HLVLRZLEIYSGOP-UHFFFAOYSA-N 0.000 claims 1
- SLEFVAGTBGMNSN-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-4-[5-methyl-4-(trifluoromethyl)-6,7-dihydro-4h-imidazo[4,5-c]pyridin-1-yl]pyridine-2-carboxamide Chemical compound FC(F)(F)C1N(C)CCC2=C1N=CN2C(C=1)=CC=NC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 SLEFVAGTBGMNSN-UHFFFAOYSA-N 0.000 claims 1
- JDUSJBULPNMZIP-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-4-[6-(2-hydroxypropan-2-yl)pyridin-3-yl]pyridine-2-carboxamide Chemical compound C1=NC(C(C)(O)C)=CC=C1C1=CC=NC(C(=O)NC=2N=C(C=CC=2)C=2N(C=NN=2)C2CC2)=C1 JDUSJBULPNMZIP-UHFFFAOYSA-N 0.000 claims 1
- ZCUZEIWNPXRKAG-UHFFFAOYSA-N n-[6-(4-cyclopropyl-1,2,4-triazol-3-yl)pyridin-2-yl]-4-quinolin-3-ylpyridine-2-carboxamide Chemical compound C=1C(C=2C=C3C=CC=CC3=NC=2)=CC=NC=1C(=O)NC(N=1)=CC=CC=1C1=NN=CN1C1CC1 ZCUZEIWNPXRKAG-UHFFFAOYSA-N 0.000 claims 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 1
- 125000004433 nitrogen atom Chemical group N* 0.000 claims 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
- 239000000041 non-steroidal anti-inflammatory agent Substances 0.000 claims 1
- 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 claims 1
- 235000020824 obesity Nutrition 0.000 claims 1
- 229940127240 opiate Drugs 0.000 claims 1
- 229940094443 oxytocics prostaglandins Drugs 0.000 claims 1
- 229960002296 paroxetine Drugs 0.000 claims 1
- 208000011906 peptic ulcer disease Diseases 0.000 claims 1
- 150000003180 prostaglandins Chemical class 0.000 claims 1
- 229940126409 proton pump inhibitor Drugs 0.000 claims 1
- 239000000612 proton pump inhibitor Substances 0.000 claims 1
- 150000007660 quinolones Chemical class 0.000 claims 1
- 230000000306 recurrent effect Effects 0.000 claims 1
- 229960002073 sertraline Drugs 0.000 claims 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 claims 1
- MNQYNQBOVCBZIQ-JQOFMKNESA-A sucralfate Chemical compound O[Al](O)OS(=O)(=O)O[C@@H]1[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](COS(=O)(=O)O[Al](O)O)O[C@H]1O[C@@]1(COS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)[C@H](OS(=O)(=O)O[Al](O)O)[C@@H](OS(=O)(=O)O[Al](O)O)O1 MNQYNQBOVCBZIQ-JQOFMKNESA-A 0.000 claims 1
- 229960004291 sucralfate Drugs 0.000 claims 1
- YROXIXLRRCOBKF-UHFFFAOYSA-N sulfonylurea Chemical class OC(=N)N=S(=O)=O YROXIXLRRCOBKF-UHFFFAOYSA-N 0.000 claims 1
- 239000013589 supplement Substances 0.000 claims 1
- 235000019364 tetracycline Nutrition 0.000 claims 1
- 229940040944 tetracyclines Drugs 0.000 claims 1
- 150000003522 tetracyclines Chemical class 0.000 claims 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 claims 1
- 229960003991 trazodone Drugs 0.000 claims 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 claims 1
- 229960004688 venlafaxine Drugs 0.000 claims 1
- 239000002132 β-lactam antibiotic Substances 0.000 claims 1
- 229940124586 β-lactam antibiotics Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
- A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Cardiology (AREA)
- Immunology (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Heart & Thoracic Surgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Claims (15)
1. Spoj sa formulom (I) za primjenu u liječenju akutnog događaja kardiovaskularnog oboljenja, gdje se spoj sa Formulom I istovremeno administrira sa terapijskim agensom, i Formula I je:
[image]
gdje:
R1 je alkil od 1-10 atoma ugljika, cikloalkil od 3-8 atoma ugljika, alkenil koji sadrži 2-10 atoma ugljika, alkinil koji sadrži 2-10 atoma ugljika, aril, heteroaril ili heterociklil, od kojih su svi izborno supstituirani sa 1, 2, ili 3 supstituenta izabrana od halo, okso, alkil sa 1 do 6 atoma ugljika, cikloalkil sa 3 do 8 atoma ugljika, heterociklil, fenil, fenoksi, halo, - CN, -O-R6, -C(O)-R6, -OC(O)-R6 -C(O)-O-R6, - N(R6)-C(O)-O-R7, -N(R6)-C(O)-R7, - N(R6)-C(O)-N(R6)(R7), i -C(O)-N(R6)(R7), gdje su alkil, cikloalkil, heterociklil, fenil, i fenoksi izborno supstituirani sa 1, 2, ili 3 supstituenta izabrana od alkil sa 1 do 6 atoma ugljika, cikloalkil sa 3 do 8 atoma ugljika, alkoksi sa 1 do 6 atoma ugljika, hidroksil, i halo;
pod uvjetom da R1 nije metil kada je R3 morfolinil ili furil;
gdje su R6 i R7 nezavisno izabrani iz grupe koja se sastoji od vodika, alkila sa 1-6 ugljikovih atoma, ili cikloalkila sa 3-8 ugljikovih atoma; ili
R6 i R7 kada su uzeti zajedno sa dušikom za koji su vezani formiraju heterociklus;
R2 je vodik, halo, cijano, alkoksi, ili alkil izborno supstituiran sa halo;
R3 je aril, heteroaril, ili heterociklil, od kojih su svi izborno supstituirani sa 1, 2 ili 3 supstituenta izabrana od alkil sa 1 do 6 atoma ugljika, alkoksi sa 1 do 6 atoma ugljika, cikloalkil sa 3 do 8 atoma ugljika, cikloalkilalkil, aril, arilalkil, heteroaril, heteroarilalkil, heterociklil, heterociklilalkil, halo, haloalkoksi, okso, -CN, -O-R6, - O-C(O)-R6, -O-C(O)-N(R6)(R7), -S-R6, -N(R6)(R7), -S(=O)-R6, -S(=O)2R6, -S(=O)2-N(R6)(R7), -S(=O)2-O-R6, -N(R6)-C(O)-R7, -N(R6)-C(O)-O-R7, -N(R6)-C(O)-N(R6)(R7), -C(O)-R6, -C(O)-O-R6, -C(O)-N(R6)(R7), i -N(R6)-S(=O)2-R7, gdje je alkil, alkoksi, cikloalkil, aril, heteroaril ili heterociklil dalje izborno supstituiran sa jednim ili više supstituenata izabranih od halo, hidroksil, okso, -CN, i -O-R6;
uz uvjet da heteroaril ili heterociklil grupa uključuje bar jedan dušikov atom prstena;
X1, X2, X3, X4, X5, X6, X7 i X8 su nezavisno C(R4) ili N, gdje je svako R4 nezavisno vodik, hidroksil, halo, alkil sa 1 do 6 ugljikovih atoma, alkoksi sa 1 do 6 ugljikovih atoma, ili cikloalkil sa 3 do 8 ugljikovih atoma, gdje je alkil ili cikloalkil dalje izborno supstituiran sa jednim ili više supstituenata izabranih od halo, hidroksil, okso, -CF3, -O-CF3, -N(R6)(R7), -C(O)-R6, -C(O)-O-R7, -C(O)-N(R6)(R7), -CN, -O-R6; ili
X5 i X6 ili X6 i X7 su vezani da formiraju fuzionirani cikloalkil, fuzionirani aril, ili fuzionirani heteroaril, od kojih su svi izborno supstituirani sa alkilom sa 1 do 6 atoma ugljika, hidroksilom, ili halo; i
uz uvjet da najmanje jedan od X2, X3, i X4 je C(R4);
najmanje dva od X5, X6, X7, i X8 su C(R4); i
najmanje jedan od X2, X3, X4, X5, X6, X7 i X8 je N.
2. Spoj za primjenu prema patentnom zahtjevu 1, gdje je terapijski agens za primjenu u liječenju bolesti ili stanja koja su kardiovaskularne prirode, poremećaja funkcije pluća, metaboličkih poremećaja ili gastrointestinalnih poremećaja; ili stanja koja imaju koristi od administracije terapijskih agenasa izabranih iz grupe koja se sastoji od antibiotika, analgetika, antidepresiva i anksiolitika.
3. Spoj za primjenu prema patentnom zahtjevu 1, gdje je terapijski agens za primjenu u liječenju kardiovaskularnih bolesti, po izboru gdje je bolest izabrana iz grupe koja se sastoji od angine, aritmija, intermitentne klaudikacije, miokardnog infarkta, insuficijencije srca i rekurentne ishemije.
4. Spoj za primjenu prema patentnom zahtjevu 1 ili patentnom zahtjevu 3, gdje je terapijski agens izabran iz grupe koja se sastoji od antianginalnih agenasa, agenasa za srčanu insuficijenciju, antitrombotičnih agenasa, antiaritmijskih agenasa, antihipertenzivnih agenasa, i agenasa za snižavanje lipida.
5. Spoj za primjenu prema patentnom zahtjevu 1, gdje je terapijski agens za primjenu u liječenju poremećaja funkcije pluća, po izboru gdje je poremećaj izabran iz grupe koja se sastoji od astme, kronične opstruktivne plućne bolesti (COPD), bronhitisa, i emfizema.
6. Spoj za primjenu prema patentnom zahtjevu 1 ili patentnom zahtjevu 5, gdje je terapijski agens bronhodilatator, kortikosteroid ili elektrolitni dodatak.
7. Spoj za primjenu prema patentnom zahtjevu 1, gdje je terapijski agens za primjenu u liječenju metaboličkih poremećaja, po izboru metabolički poremećaj je izabran iz grupe koja se sastoji od dijabetesa, metaboličkog sindroma, dislipidemije, gojaznosti, intolerancije glukoze, hipertenzije, povišenog serumskog kolesterola, i povišenih triglicerida.
8. Spoj za primjenu prema patentnom zahtjevu 1 ili patentnom zahtjevu 7, gdje je terapijski agens izabran iz grupe koja se sastoji od antihipertenzivnih agenasa, agenasa za snižavanje lipida, inzulina, sulfonilurea, bigvanidina, inhibitora alfa-glukozidaze, i inkretinskih mimetika.
9. Spoj za primjenu prema patentnom zahtjevu 1, gdje je terapijski agens za primjenu u liječenju gastrointestinalnih poremećaja, po izboru gastrointestinalni poremećaj je izabran iz grupe koja se sastoji od bolesti gastroezofagealnog refluksa (GERD), inflamatorne bolesti crijeva (IBD), gastroenteritisa, gastritisa i peptičke ulkusne bolesti, i pankreatitisa.
10. Spoj za primjenu prema patentnom zahtjevu 1 ili patentnom zahtjevu 9, gdje je terapijski agens izabran iz grupe koja se sastoji od inhibitora protonske pumpe, H2 blokatora, prostaglandina, sukralfata i antacida.
11. Spoj za primjenu prema patentnom zahtjevu 1, gdje je terapijski agens antibiotski agens izabran iz grupe koja se sastoji od β-laktamskih antibiotika, tetraciklina, makrolidnih antibiotika, aminoglikozida, hinolona, cikličnih peptida, linkozamida, i sulfa antibiotika.
12. Spoj za primjenu prema patentnom zahtjevu 1, gdje je terapijski agens analgetik izabran iz grupe koja se sastoji od opijata, morfijskih mimetika, NSAIL-a, i COX-2 inhibitora.
13. Spoj za primjenu prema patentnom zahtjevu 1, gdje je terapijski agens antidepresivni i anksiolitički agens izabran iz grupe koja se sastoji od benzodiazepina, enzodiazepina, barbiturata, glutetimida, kloral hidrata, meprobamata, sertralina, escitaloprama, fluoksetina, venlafaksina, citaloprama, paroksetina, trazodona, amitriptilina, i bupropiona.
14. Farmaceutska kompozicija koja sadrži spoj sa Formulom I kao što je definirano u patentnom zahtjevu 1 i terapijski agens kao što je definirano u bilo kojem od patentnih zahtjeva 4, 6, 8 i 10 do 13.
15. Spoj za primjenu prema bilo kojem od patentnih zahtjeva 1 do 13 ili farmaceutska kompozicija prema patentnom zahtjevu 14, gdje je spoj sa Formulom I izabrano iz grupe koja se sastoji od:
6-ciklopropil-N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
4-(4-ciklopropil-1H-imidazol-1-il)-N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(2-ciklopropilpirimidin-5-il)pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-6-(2,2,2-trifluoroetil)-3,4'-bipiridin-2'-karboksamida;
4-(imidazo[1,2-a]piridin-3-il)-N-(3-(4-metil-4H-1,2,4-triazol-3-il)fenil)-pikolinamida;
4-(2-aminopirimidin-5-il)-N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-fenilpikolinamida;
N-(3-(4-(tetrahidro-2H-piran-4-il)-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1 ,2,4-triazol-3-il)fenil)-4-(1H-imidazol-1-il)pikolinamida;
N-(3-(4-metil-4H-1,2,4-triazol-3-il)fenil)-4-fenilpikolinamida;
N-(3-(4-(3-amino-3-oksopropil)-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(1H-1,2,4-triazol-1-il)pikolinamida;
N-(3-(4-metil-4H-1,2,4-triazol-3-il)fenil)-6-fenilpikolinamida;
N-(3-(4-(2-acetamidoetil)-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-metil-4H-1,2,4-triazol-3-il)fenil)-4-(4-metilpiperazin-1-il)pikolinamida;
N-(3-(4-metil-4H-1,2,4-triazol-3-il)fenil)-2,3'-bipiridin-6-karboksamida;
N-(3-(4-metil-4H-1,2,4-triazol-3-il)fenil)-4-morfolinopikolinamida;
N-(3-(4-metil-4H-1,2,4-triazol-3-il)fenil)-6-(hinolin-6-il)pikolinamida;
(R)-N-(3-(4-(1-hidroksipropan-2-il)-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-6-hidroksi-3,4'-bipiridin-2'-karboksamida;
(S)-N-(3-(4-(1-hidroksipropan-2-il)-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-metil-4H-1,2,4-triazol-3-il)fenil)-4-(3-oksopiperazin-1-il)pikolinamida;
N-(3-(4-metil-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-6-metoksi-3,4'-bipiridin-2'-karboksamida;
4-(3-aminopirolidin-1-il)-N-(3-(4-metil-4H-1,2,4-triazol-3-il)fenil)pikolinamida;
6-amino-N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
(R)-N-(3-(4-(2-hidroksipropil)-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
5-metoksi-N-(3-(4-metil-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
Metil 2'-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenilkarbamoil)-3,4'-bipiridin-6-il-karbamata;
(S)-N-(3-(4-(2-hidroksipropil)-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
4-(1-metil-1H-imidazol-5-il)-N-(3-(4-metil-4H-1 ,2,4-triazol-3-il)fenil)pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(1-metil-1H-imidazol-5-il) pikolinamida;
4-(1H-benzo[d]imidazol-1-il)-N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil) pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(2,4-dimetoksipirimidin-5-il) pikolinamida;
N-(3-(4-((1-hidroksiciklopropil)metil)-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(4-fenil-1H-imidazol-1-il) pikolinamida;
N-(3-(4-ciklobutil-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
N2'-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2',6-dikarboksamida;
(S)-N-(3-(4-(1,1,1-trifluoropropan-2-il)-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopentil-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-6-(trifluorometil)-3,4'-bipiridin-2'-karboksamida;
N2'-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2',5-dikarboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(2-metil-1H-imidazol-1-il) pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-6-metil-3,4'-bipiridin-2'-karboksamida;
5-cijano-N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(4-metil-1H-imidazol-1-il) pikolinamida;
2-amino-N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(4,5-dimetil-1H-imidazol-1-il) pikolinamida;
N-(3-(4-((1S,2S)-2-metilciklopropil)-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-2-metoksi-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(4-(trifluorometil)-1H-imidazol-1-il) pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-6-(2,2,2-trifluoroetoksi)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(1-metil-1H-pirazol-4-il) pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(2-metoksipirimidin-5-il) pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-metil-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(imidazo[1,2-a]piridin-3-il) pikolinamida;
6'-metil-N-(3-(4-metil-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-(2,2,2-trifluoroetil)-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
6-klor-[3,2',5',4"]terpiridin-2"-karboksilna kiselina [3-(4-ciklopropil-4H-[1,2,4]triazol-3-il)-fenil]amida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-6-(pirolidin-1-il)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-5-(trifluorometil)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(1,2-dimetil-1H-imidazol-5-il) pikolinamida;
4-(1H-benzo[d][1,2,3]triazol-1-il)-N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil) pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(4-sulfamoilfenil)pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-5-metoksi-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-6-fluor-5-metil-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-5-fluor-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-2-metil-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(4,5,6,7-tetrahidro-1H-benzo[d] imidazol-1-il)pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(4-(N-metilsulfamoil)fenil) pikolinamida;
N5-terc-butil-N2'-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2',5-dikarboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(pirazin-2-il)pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(4-(N-izopropilsulfamoil)fenil) pikolinamida;
5-klor-N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(3-(metilsulfonil)fenil)pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(izohinolin-4-il)pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(2-(metilsulfonil)fenil)pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(1,5-dimetil-1H-pirazol-4-il) pikolinamida;
6-ciklobutil-N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-6-izopropil-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(4-(metilsulfonil)fenil)pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-6-(dimetilamino)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(1H-pirolo[2,3-b]piridin-5-il) pikolinamida;
6-ciklopropoksi-N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(1H-imidazo[4,5-b]piridin-1-il) pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-6-fluor-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(4-(2-oksoimidazolidin-1-il)fenil) pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(3H-imidazo[4,5-b]piridin-3-il) pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-6-izopropoksi-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(1H-imidazo[4,5-c]piridin-1-il) pikolinamida;
6-ciklobutoksi-N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-3,4',-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(hinolin-3-il)pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(4-(N-ciklopropilsulfamoil)fenil) pikolinamida;
6-ciklopentil-N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(imidazo[2,1-b][1,3,4]tiadiazol-5-il) pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(5-ciklopropilpirazin-2-il) pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-6-(1-metil-2-oksopirolidin-3-il)-3,4'-bipiridin-2'-karboksamida;
4-(4-klor-1H-imidazol-1-il)-N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil) pikolinamida;
6-ciklopropil-N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-5-fluor-3,4'-bipiridin-2'-karboksamida;
(S)-4-(4-ciklopropil-1H-imidazol-1-il)-N-(3-(4-(3-metilbutan-2-il)-4H-1,2,4-triazol-3-il)fenil)pikolinamida;
6'-ciklopropil-N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-2,3'-bipiridin-6-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(5-metil-4-(trifluorometil)-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-1-il)pikolinamida;
4-(5-ciklopropil-4-metil-4H-1,2,4-triazol-3-il)-N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)pikolinamida;
4-(3-ciklopropil-1,2,4-oksadiazol-5-il)-N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(3-metil-1,2,4-oksadiazol-5-il) pikolinamida;
6-ciklopropil-N-(3-(4-(3-hidroksibutan-2-il)-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(5-(1-hidroksietil)-1,3,4-oksadiazol-2-il)pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(6-metoksihinolin-3-il) pikolinamida;
6-ciklopropil-N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-5'-metil-3,4'-bipiridin-2'-karboksamida;
6-ciklopropil-N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-6'-metil-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(1-(2,2,2-trifluoroetil)-1H-pirolo[3,2-b]piridin-6-il)pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(1-izopropil-1H-pirolo[3,2-b]piridin -6-il)pikolinamida;
(S)-6-ciklopropil-N-(3-(4-(3,3-dimetilbutan-2-il)-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-sek-butil-4H-1,2,4-triazol-3-il)fenil)-6-ciklopropil-3,4'-bipiridin-2'-karboksamida;
(S)-6-ciklopropil-N-(3-(4-(1-ciklopropiletil)-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
6-ciklopropil-N-(3-(4-(pentan-3-il)-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
(S)-6-ciklopropil-N-(3-(4-(1-metoksipropan-2-il)-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
(S)-N-(3-(4-sek-butil-4H-1,2,4-triazol-3-il)fenil)-6-ciklopropil-3,4'-bipiridin-2'-karboksamida;
(S)-6-ciklopropil-N-(3-(4-(3-metilbutan-2-il)-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
(R)-6-ciklopropil-N-(3-(4-(1-(2,6-dimetilfenoksi)propan-2-il)-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
(S)-6-ciklopropil-N-(3-(4-(1,1,1-trifluoropropan-2-il)-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklobutil-4H-1,2,4-triazol-3-il)fenil)-6-ciklopropil-3,4'-bipiridin-2'-karboksamida;
(S)-6-ciklopropil-N-(3-(4-(1-feniletil)-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
6-ciklopropil-N-(3-(4-izopropil-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-(ciklopropilmetil)-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
4-(4-ciklopropil-2-metil-1H-imidazol-1-il)-N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)pikolinamida;
4-(4-ciklopropil-1H-imidazol-1-il)-N-(3-(4-izopropil-4H-1,2,4-triazol-3-il)fenil) pikolinamida;
4-(4-ciklopropil-1H-imidazol-1-il)-N-(3-(4-(ciklopropilmetil)-4H-1,2,4-triazol-3-il)fenil)pikolinamida;
4-(4-ciklopropil-1H-imidazol-1-il)-N-(3-(4-(1-feniletil)-4H-1H-1,2,4-triazol-3-il)fenil) pikolinamida;
(R)-4-(4-ciklopropil-1H-imidazol-1-il)-N-(3-(4-(1,1,1-trifluoropropan-2-il)-4H-1,2,4-triazol-3-il)fenil)pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(1,5-naftiridin-3-il)pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(4-(trifluorometil)-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-1-il)pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(4-(perfluoroetil)-1H-imidazol-1-il)pikolinamida;
4-(3-ciklopropil-1H-1,2,4-triazol-1-il)-N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il) fenil)pikolinamida;
4-(5-ciklopropil-1H-1,2,4-triazol-1-il)-N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il) fenil)pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(4-(2,2,2-trifluoro-1-hidroksietil)-1H-imidazol-1-il)pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(2-etilpirimidin-5-il)pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-5-etil-3,4'-bipiridin-2'-karboksamida;
6-ciklopropil-N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)-4-fluorofenil)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)-4-fluorofenil)-6-etil-3,4'-bipiridin-2'-karboksamida;
6-terc-butil-N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(5,6,7,8-tetrahidro-1,6-naftiridin-3-il)pikolinamida;
6-ciklopropil-N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)-2-fluorofenil)-3,4'-bipiridin-2'-karboksamida;
5-ciklopropil-N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)-2-fluorofenil)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(4-etil-1H-imidazol-1-il) pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(6-(2,2,2-trifluoroetil)-5,6,7,8-tetrahidro-1,6-naftiridin-3-il)pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(4-izopropil-1H-imidazol-1-il) pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-6-(2-hidroksipropan-2-il)-3,4'-bipiridin-2'-karboksamida;
6-ciklopropil-N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)-5-fluorofenil)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)-5-fluorofenil)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(6-izopropil-5,6,7,8-tetrahidro-1,6-naftiridin-3-il)pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(6-metil-5,6,7,8-tetrahidro-1,6-naftiridin-3-il)pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(3-hidroksipiperidin-1-il) pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(4-etil-3-oksopiperazin-1-il) pikolinamida;
N-(3-(4-izopropil-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-6-propil-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-6-neopentil-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(1-metil-2-fenil-1H-imidazol-5-il) pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(4-(etilsulfonil)fenil)-pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(4-(izopropilsulfonil)fenil) pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-6-(etilamino)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-6-(ciklopropilamino)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-6'-(trifluorometil)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(hinolin-3-il)-6-(trifluorometil) pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(1H-pirolo[3,2-b]piridin-6-il) pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(4-ciklopropilfenil)pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-6-(metiltio)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-6-(izobutiltio)-3,4'-bipiridin-2'-karboksamida;
5-klor-6-ciklopropil-N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-6-(2-metoksietilamino)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(4-(metilsulfonil)piperazin-1-il) pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-6-etil-5-fluor-3,4'-bipiridin-2'-karboksamida;
5-klor-N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-6-etil-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-5,6-dietil-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(furo[3,2-b]piridin-6-il) pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(3-metil-3H-imidazo[4,5-b]piridin-6-il)pikolinamida;
6-ciklopropil-N-(3-(4-(2-fenilciklopropil)-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
(S)-4-(4-ciklopropil-1H-imidazol-1-il)-N-(3-(4-(1,1,1-trifluoropropan-2-il)-4H-1,2,4-triazol-3-il)fenil)pikolinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-6-(ciklopropilmetil)-3,4'-bipiridin-2'-karboksamida;
4-(5-ciklopropil-1,3,4-tiadiazol-2-il)-N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)pikolinamida;
N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-3-(hinolin-3-il)benzamida;
N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-5-(6-ciklopropilpiridin-3-il)-2,4-difluorobenzamida;
4-klor-N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-5-(6-ciklopropilpiridin-3-il)-2-fluorobenzamida;
N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-3-(4-(2,2,2-trifluoro-1-metoksietil)-1H-imidazol-1-il)benzamida;
3-(4-ciklopropil-1H-imidazol-1-il)-N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-4-metoksibenzamida;
4-klor-3-(4-ciklopropil-1H-imidazol-1-il)-N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)benzamida;
N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-5-(6-ciklopropilpiridin-3-il)-2-fluorobenzamida;
3-(4-ciklopropil-1H-imidazol-1-il)-N-(6-(4-izopropil-4H-1,2,4-triazol-3-il)piridin-2-il)benzamida;
(S)-3-(4-ciklopropil-1H-imidazol-1-il)-N-(6-(4-(1-feniletil)-4H-1H-1,2,4-triazol-3-il)piridin-2-il)benzamida;
N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-3-(1,5-naftiridin-3-il) benzamida;
3-(4-ciklopropil-1H-imidazol-1-il)-N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)benzamida;
N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-3-(4-izopropil-1H-imidazol-1-il)benzamida;
3-(4-ciklopropil-1H-imidazol-1-il)-N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-2-metilbenzamida;
5-(4-ciklopropil-1H-imidazol-1-il)-N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-2-metilbenzamida;
3-(4-ciklopropil-1H-imidazol-1-il)-N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-4-metilbenzamida;
N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-3-(6-(2-hidroksipropan-2-il)piridin-3-il)benzamida;
3-(4-ciklopropil-1H-imidazol-1-il)-N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-5-fluorobenzamida;
N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-3-(4-(2,2,2-trifluoro-1-hidroksietil)-1H-imidazol-1-il)benzamida;
3-(4-ciklopropil-1H-imidazol-1-il)-N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-5-metilbenzamida;
N-(6-(4-ciklopropil-4H-1 ,2,4-triazol-3-il)piridin-2-il)-3-(4,5-dimetil-1H-imidazol-1-il)benzamida;
N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-3-(4,5,6,7-tetrahidro-1H-benzo[d]imidazol-1-il)benzamida;
1-(3-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-ilkarbamoil)fenil)-5-metil-1H-imidazol-4-karboksilne kiseline;
(S)-3-(4-ciklopropil-1H-imidazol-1-il)-N-(6-(4-(1-feniletil)-4H-1H-1,2,4-triazol-3-il)piridin-2-il)benzamida;
(S)-3-(4,5-dimetil-1H-imidazol-1-il)-N-(6-(4-(1,1,1-trifluoropropan-2-il)-4H-1,2,4-triazol-3-il)piridin-2-il)benzamida;
N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-3-(6-ciklopropilpiridin-3-il) benzamida;
N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-3-(piridin-3-il)benzamida;
N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-5-(6-ciklopropilpiridin-3-il)-2,4-difluorobenzamida;
4-klor-N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-5-(6-ciklopropilpiridin-3-il)-2-fluorobenzamida;
3-(4-ciklopropil-1H-1,2,3-triazol-1-il)-N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il) piridin-2-il)benzamida
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(6-ciklopropilpiridin-3-il)-7,8-dimetilhinolin-2-karboksamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-4-(piridin-3-il)hinolin-2-karboksamida;
N-(3-(4-metil-4H-1,2,4-triazol-3-il)fenil)-3,3'-bipiridin-5-karboksamida;
N-(3-(4-metil-4H-1,2,4-triazol-3-il)fenil)-5-fenilnikotinamida;
N-(3-(4-metil-4H-1,2,4-triazol-3-il)fenil)-2-fenil izonikotinamida;
6'-ciklopropil-N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-2,3'-bipiridin-6-karboksamida;
6'-ciklopropil-N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-2,3'-bipiridin-4-karboksamida;
5-(2,5-difluorofenil)-N-(3-(4-metil-4H-1,2,4-triazol-3-il)fenil)nikotinamida;
N-(3-(4-ciklopropil-4H-1,2,4-triazol-3-il)fenil)-6-(6-ciklopropilpiridin-3-il)pirimidin-4-karboksamida;
6'-ciklopropil-N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-2,3'-bipiridin-4-karboksamida;
2-hidroksi-N-(3-(4-metil-4H-1,2,4-triazol-3-il)fenil)-6-fenilpirimidin-4-karboksamida;
N-(6-(1-ciklopropil-1H-imidazol-5-il)piridin-2-il)-4-(4,5-dimetil-1H-imidazol-1-il) pikolinamida;
N-(6-(1-ciklopropil-1H-imidazol-5-il)piridin-2-il)-6-(2-hidroksipropan-2-il)-3,4'-bipiridin-2'-karboksamida;
N-(6-(1-ciklopropil-1H-imidazol-5-il)piridin-2-il)-4-(hinolin-3-il)pikolinamida;
6-ciklopropil-N-(6-(1-ciklopropil-1H-imidazol-5-il)piridin-2-il)-3,4'-bipiridin-2'-karboksamida;
6-ciklopropil-N-(3-(1-ciklopropil-1H-imidazol-5-il)fenil)-3,4'-bipiridin-2'-karboksamida;
N-(3-(1-ciklopropil-1H-imidazol-5-il)fenil)-3,4'-bipiridin-2'-karboksamida;
4-(1H-benzo[d]imidazol-1-il)-N-(3-(1-ciklopropil-1H-imidazol-5-il)fenil) pikolinamida;
N-(3-(1-ciklopropil-1H-imidazol-5-il)fenil)-4-(hinolin-3-il)pikolinamida;
6-ciklopropil-N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-3,4'-bipiridin-2'-karboksamida;
N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-4-(4,5-dimetil-1H-imidazol-1-il)pikolinamida;
N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-6-(2-hidroksipropan-2-il)-3,4'-bipiridin-2'-karboksamida.
6'-ciklopropil-N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-2,3'-bipiridin-6-karboksamida;
N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-4-(5-metil-4-(trifluorometil)-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-1-il)pikolinamida;
6-ciklopropil-N-(6-(4-((2R)-3-hidroksibutan-2-il)-4H-1,2,4-triazol-3-il)piridin-2-il)-3,4'-bipiridin-2'-karboksamida;
6-ciklopropil-N-(6-(4-((2S,3R)-3-hidroksibutan-2-il)-4H-1,2,4-triazol-3-il)piridin-2-il)-3,4'-bipiridin-2'-karboksamida;
6-ciklopropil-N-(6-(4-((2S,3S)-3-hidroksibutan-2-il)-4H-1,2,4-triazol-3-il)piridin-2-il)-3,4'-bipiridin-2'-karboksamida;
6-ciklopropil-N-(6-(4-(1-(pirolidin-1-il)propan-2-il)-4H-1,2,4-triazol-3-il)piridin-2-il)-3,4'-bipiridin-2'-karboksamida;
N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-4-(6-ciklopropilpiridin-3-il)-7,8-dimetilhinolin-2-karboksamida;
4-(4-ciklopropil-1H-imidazol-1-il)-N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)hinolin-2-karboksamida;
N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-4-(6-ciklopropilpiridin-3-il)hinolin-2-karboksamida;
4-(4-ciklopropil-2-metil-1H-imidazol-1-il)-N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)pikolinamida;
N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-4-(4,5,6,7-tetrahidro-1H-benzo[d]imidazol-1-il)pikolinamida;
N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-4-(4-(trifluorometil)-1H-imidazol-1-il)pikolinamida;
N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-4-(4-(trifluorometil)-4,5,6,7-tetrahidro-1H-imidazo[4,5-c]piridin-1-il)pikolinamida;
N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-4-(4-(perfluoroetil)-1H-imidazol-1-il)pikolinamida;
4-(3-ciklopropil-1H-1,2,4-triazol-1-il)-N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)pikolinamida;
N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-4-(4-(2,2,2-trifluoro-1-hidroksietil)-1H-imidazol-1-il)pikolinamida;
6-ciklopropil-N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-5'-metil-3,4'-bipiridin-2'-karboksamida;
6-ciklopropil-N-(2-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-4-il)-3,4'-bipiridin-2'-karboksamida;
N-(2-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-4-il)-4-(hinolin-3-il)pikolinamida;
N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-4-(4-metil-1H-imidazol-1-il)pikolinamida;
N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-4-(4-izopropil-1H-imidazol-1-il)pikolinamida;
4-(4-ciklopropil-1H-imidazol-1-il)-N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)pikolinamida;
N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-4-(3-hidroksipiperidin-1-il)pikolinamida;
6-ciklopropil-N-(6-(4-izopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-3,4'-bipiridin-2'-karboksamida;
N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-4-(4-etil-3-oksopiperazin-1-il)pikolinamida;
(R)-6-ciklopropil-N-(6-(4-(1,1,1-trifluoropropan-2-il)-4H-1,2,4-triazol-3-il)piridin-2-il)-3,4'-bipiridin-2'-karboksamida;
N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-4-(4-(N-metilsulfamoil)fenil)pikolinamida;
N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-4-(hinolin-3-il)pikolinamida;
N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-4-(4-fenil-1H-imidazol-1-il)pikolinamida;
N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-4-(4-(metilsulfonil)fenil)pikolinamida
N-(6-(4-ciklopropil-4H-1,2,4-triazol-3-il)piridin-2-il)-3,4'-bipiridin-2'-karboksamida;
6-ciklopropil-N-(3-(4-fenil-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
6-ciklopropil-N-(3-(4-(piridin-2-il)-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
6-ciklopropil-N-(3-(4-(piridin-3-il)-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
6-ciklopropil-N-(3-(4-(piridin-4-il)-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
6-ciklopropil-N-(3-(4-(pirimidin-5-il)-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
N-(3-(4-(but-2-inil)-4H-1,2,4-triazol-3-il)fenil)-6-ciklopropil-3,4'-bipiridin-2'-karboksamida;
6-ciklopropil-N-(3-(4-(1-(piridin-3-iloksi)propan-2-il)-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
6-ciklopropil-N-(3-(4-(1-(2,2,2-trifluoroetoksi)propan-2-il)-4H-1,2,4-triazol-3-il)fenil)-3,4'-bipiridin-2'-karboksamida;
4-(4-ciklopropil-1H-imidazol-1-il)-N-(3-(4-fenil-4H-1,2,4-triazol-3-il)fenil)pikolinamida;
4-(4-ciklopropil-1H-imidazol-1-il)-N-(3-(4-(piridin-2-il)-4H-1,2,4-triazol-3-il)fenil)pikolinamida;
4-(4-ciklopropil-1H-imidazol-1-il)-N-(3-(4-(piridin-3-il)-4H-1,2,4-triazol-3-il)fenil)pikolinamida;
4-(4-ciklopropil-1H-imidazol-1-il)-N-(3-(4-(piridin-4-il)-4H-1,2,4-triazol-3-il)fenil)pikolinamida;
4-(4-ciklopropil-1H-imidazol-1-il)-N-(3-(4-(pirimidin-5-il)-4H-1 ,2,4-triazol-3-il)fenil)pikolinamida;
N-(3-(4-(but-2-inil)-4H-1,2,4-triazol-3-il)fenil)-4-(4-ciklopropil-1H-imidazol-1 - il)pikolinamida;
4-(4-ciklopropil-1H-imidazol-1-il)-N-(3-(4-(1-(piridin-3-iloksi)propan-2-il)-4H-1,2,4-triazol-3-il)fenil)pikolinamida; i
4-(4-ciklopropil-1H-imidazol-1-il)-N-(3-(4-(1-(2,2,2-trifluoroetoksi)propan-2-il)-4H-1,2,4-triazol-3-il)fenil)pikolinamida.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US22507609P | 2009-07-13 | 2009-07-13 | |
US22507909P | 2009-07-13 | 2009-07-13 | |
US28926309P | 2009-12-22 | 2009-12-22 | |
EP15151030.2A EP2933252B1 (en) | 2009-07-13 | 2010-07-12 | Apoptosis signal-regulating kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
HRP20180413T1 true HRP20180413T1 (hr) | 2018-04-20 |
Family
ID=42670422
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20150185AT HRP20150185T1 (hr) | 2009-07-13 | 2015-02-17 | Inhibitori kinaza koji reguliraju signalne puteve u apoptozi |
HRP20180413TT HRP20180413T1 (hr) | 2009-07-13 | 2018-03-09 | Inhibitori kinaza koji reguliraju signalne puteve u apoptozi |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HRP20150185AT HRP20150185T1 (hr) | 2009-07-13 | 2015-02-17 | Inhibitori kinaza koji reguliraju signalne puteve u apoptozi |
Country Status (28)
Country | Link |
---|---|
US (7) | US8378108B2 (hr) |
EP (4) | EP2933252B1 (hr) |
JP (4) | JP5745721B2 (hr) |
KR (3) | KR20170081722A (hr) |
CN (1) | CN102482257B (hr) |
AR (1) | AR077564A1 (hr) |
AU (1) | AU2010273597B2 (hr) |
BR (1) | BR112012000894A2 (hr) |
CA (1) | CA2767894C (hr) |
CY (1) | CY1119889T1 (hr) |
DK (2) | DK2933252T3 (hr) |
ES (3) | ES2662397T3 (hr) |
HK (2) | HK1170482A1 (hr) |
HR (2) | HRP20150185T1 (hr) |
HU (1) | HUE038529T2 (hr) |
LT (1) | LT2933252T (hr) |
ME (1) | ME02104B (hr) |
MX (1) | MX2012000708A (hr) |
NO (1) | NO2933252T3 (hr) |
NZ (1) | NZ597533A (hr) |
PL (3) | PL3363797T3 (hr) |
PT (3) | PT2933252T (hr) |
RS (2) | RS53951B1 (hr) |
SI (3) | SI2933252T1 (hr) |
SM (1) | SMT201500090B (hr) |
TW (3) | TWI625121B (hr) |
UY (1) | UY32786A (hr) |
WO (1) | WO2011008709A1 (hr) |
Families Citing this family (193)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8536186B2 (en) | 2008-08-04 | 2013-09-17 | Chdi Foundation, Inc. | Certain kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
TWI625121B (zh) * | 2009-07-13 | 2018-06-01 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
MX2012008346A (es) | 2010-01-25 | 2012-11-12 | Chdi Foundation Inc | Determinados inhibidores de cinurenina-3-monooxigenasa, composiciones farmceuticas y metodos de uso de los mismos. |
AU2011272782B2 (en) * | 2010-07-02 | 2014-11-27 | Gilead Sciences, Inc. | Apoptosis signal-regulating kinase inhibitors |
EP2598660B1 (en) | 2010-07-26 | 2017-03-15 | Biomatrica, INC. | Compositions for stabilizing dna, rna and proteins in blood and other biological samples during shipping and storage at ambient temperatures |
EP2598661B1 (en) | 2010-07-26 | 2017-09-27 | Biomatrica, INC. | Compositions for stabilizing dna, rna and proteins in saliva and other biological samples during shipping and storage at ambient temperatures |
US9045485B2 (en) | 2010-12-16 | 2015-06-02 | Convergence Pharmaceuticals Limited | ASK 1 inhibiting pyrrolopyrimidine derivatives |
AU2012300246A1 (en) | 2011-08-30 | 2014-03-06 | Chdi Foundation, Inc. | Kynurenine-3-monooxygenase inhibitors, pharmaceutical compositions, and methods of use thereof |
PL2750677T4 (pl) | 2011-08-30 | 2017-12-29 | Chdi Foundation, Inc. | Inhibitory 3-monooksygenazy kinureninowej, kompozycje farmaceutyczne i sposoby ich stosowania |
AU2015201188B2 (en) * | 2012-01-27 | 2016-12-15 | Gilead Sciences, Inc. | Apoptosis signal-regulating kinase inhibitor |
UY34573A (es) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
US9725703B2 (en) | 2012-12-20 | 2017-08-08 | Biomatrica, Inc. | Formulations and methods for stabilizing PCR reagents |
UY35212A (es) * | 2012-12-21 | 2014-06-30 | Gilead Sciences Inc | Inhibidores de la quinasa que regula la señal de la apoptosis |
AU2014205483B2 (en) | 2013-01-10 | 2017-11-30 | Gilead Sciences, Inc. | Non-selective kinase inhibitors |
KR20160061911A (ko) | 2013-04-08 | 2016-06-01 | 데니스 엠. 브라운 | 최적하 투여된 화학 화합물의 치료 효과 |
WO2015002729A2 (en) | 2013-06-13 | 2015-01-08 | Biomatrica, Inc. | Cell stabilization |
US9249151B2 (en) * | 2013-08-23 | 2016-02-02 | Boehringer Ingelheim International Gmbh | Bis-amido pyridines |
CN111743901B (zh) | 2013-10-11 | 2023-09-12 | 普尔莫凯恩股份有限公司 | 喷雾干燥制剂 |
WO2015070366A1 (en) * | 2013-11-12 | 2015-05-21 | Merck Sharp & Dohme Corp. | Aryl linked imidazole and triazole derivatives and methods of use thereof for improving the pharmacokinetics of a drug |
CA2931615A1 (en) | 2013-11-26 | 2015-06-04 | Gilead Sciences, Inc. | Therapies for treating myeloproliferative disorders |
GB201321748D0 (en) * | 2013-12-09 | 2014-01-22 | Ucb Pharma Sa | Therapeutic agents |
CA2937320A1 (en) | 2014-01-20 | 2015-07-23 | Gilead Sciences, Inc. | Therapies for treating cancers |
WO2015187499A1 (en) | 2014-06-03 | 2015-12-10 | Gilead Sciences, Inc. | Use of an ask1 inhibitor for the treatment of liver disease, optionally in combination with a loxl2 inhibitor |
WO2015191632A1 (en) | 2014-06-10 | 2015-12-17 | Biomatrica, Inc. | Stabilization of thrombocytes at ambient temperatures |
EP3169684B1 (en) | 2014-07-17 | 2019-06-26 | CHDI Foundation, Inc. | Combination of kmo inhibitor 6-(3-chloro-4-cyclopropoxyphenyl)pyrimidine-4-carboxylic acid with antiviral agent for treating hiv related neurological disorders |
TW201618781A (zh) | 2014-08-13 | 2016-06-01 | 吉李德科學股份有限公司 | 治療肺高血壓之方法 |
SG11201701723XA (en) | 2014-09-24 | 2017-04-27 | Gilead Sciences Inc | Methods of treating liver disease |
MA41252A (fr) * | 2014-12-23 | 2017-10-31 | Gilead Sciences Inc | Formes solides d'un inhibiteur d'ask 1 |
PL3237404T3 (pl) * | 2014-12-23 | 2021-05-04 | Gilead Sciences, Inc. | Procesy wytwarzania inhibitorów ask1 |
TW201639573A (zh) | 2015-02-03 | 2016-11-16 | 吉李德科學股份有限公司 | 有關治療癌症之合併治療 |
CN107108615B (zh) | 2015-03-04 | 2020-11-20 | 吉利德科学公司 | Toll样受体调节性4,6-二氨基-吡啶并[3,2-D]嘧啶化合物 |
NZ738525A (en) | 2015-07-06 | 2019-03-29 | Gilead Sciences Inc | Cot modulators and methods of use thereof |
WO2017007938A1 (en) * | 2015-07-09 | 2017-01-12 | Janssen Pharmaceutica Nv | Substituted 4-azaindoles and their use as glun2b receptor modulators |
KR200483190Y1 (ko) | 2015-09-11 | 2017-04-13 | 주식회사 엔젤악기 | 바로크식 운지법과 독일식 운지법의 선택 적용이 가능한 리코더 링 |
WO2017059224A2 (en) | 2015-10-01 | 2017-04-06 | Gilead Sciences, Inc. | Combination of a btk inhibitor and a checkpoint inhibitor for treating cancers |
US20170107216A1 (en) | 2015-10-19 | 2017-04-20 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
AU2016358100B2 (en) | 2015-11-19 | 2021-05-27 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
CN113588501A (zh) | 2015-12-08 | 2021-11-02 | 生物马特里卡公司 | 降低红细胞沉降速率 |
US10316049B2 (en) | 2015-12-17 | 2019-06-11 | Gilead Sciences, Inc. | Tank-binding kinase inhibitor compounds |
WO2017106634A1 (en) * | 2015-12-17 | 2017-06-22 | Incyte Corporation | N-phenyl-pyridine-2-carboxamide derivatives and their use as pd-1/pd-l1 protein/protein interaction modulators |
DK3394033T3 (da) | 2015-12-22 | 2021-01-04 | Incyte Corp | Heterocykliske forbindelser som immunmodulatorer |
CA3016081A1 (en) | 2016-03-04 | 2017-09-08 | Gilead Sciences, Inc. | Compositions and combinations of autotaxin inhibitors |
TW201808906A (zh) | 2016-03-16 | 2018-03-16 | 拜耳作物科學股份有限公司 | 作為殺蟲劑之經取代吡啶化合物 |
EP3440113A1 (en) | 2016-04-08 | 2019-02-13 | Gilead Sciences, Inc. | Compositions and methods for treating cancer, inflammatory diseases and autoimmune diseases |
MA44860A (fr) | 2016-05-06 | 2019-03-13 | Incyte Holdings Corp | Composés hétérocycliques utilisés comme immunomodulateurs |
US20170342060A1 (en) | 2016-05-26 | 2017-11-30 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
CA3027209C (en) | 2016-06-13 | 2022-08-16 | I-Mab | Anti-pd-l1 antibodies and uses thereof |
BR112018076534A2 (pt) | 2016-06-20 | 2019-04-02 | Incyte Corporation | compostos heterocíclicos como imunomoduladores |
ES2930092T3 (es) | 2016-07-14 | 2022-12-07 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
CA3032813A1 (en) | 2016-08-04 | 2018-02-08 | Gilead Sciences, Inc. | Cobicistat for use in cancer treatments |
EP3504198B1 (en) | 2016-08-29 | 2023-01-25 | Incyte Corporation | Heterocyclic compounds as immunomodulators |
US10640499B2 (en) | 2016-09-02 | 2020-05-05 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
EP3507276B1 (en) | 2016-09-02 | 2021-11-03 | Gilead Sciences, Inc. | Toll like receptor modulator compounds |
KR102543227B1 (ko) | 2016-10-27 | 2023-06-13 | 풀모킨 인코포레이티드 | 폐고혈압을 치료하기 위한 병용 요법 |
WO2018085069A1 (en) | 2016-11-03 | 2018-05-11 | Gilead Sciences, Inc. | Combination of a bcl-2 inhibitor and a bromodomain inhibitor for treating cancer |
CA3042398A1 (en) | 2016-11-11 | 2018-05-17 | Gilead Sciences, Inc. | Methods of treating liver disease |
WO2018090869A1 (zh) * | 2016-11-16 | 2018-05-24 | 广东东阳光药业有限公司 | 酰胺衍生物及其在药物中的应用 |
CA3042731A1 (en) * | 2016-11-22 | 2018-05-31 | Dana-Farber Cancer Institute, Inc. | Inhibitors of interleukin-1 receptor-associated kinases and uses thereof |
US20180141939A1 (en) | 2016-11-22 | 2018-05-24 | Gilead Sciences, Inc. | Solid forms of a bet inhibitor |
EP3558989B1 (en) | 2016-12-22 | 2021-04-14 | Incyte Corporation | Triazolo[1,5-a]pyridine derivatives as immunomodulators |
EP3558985B1 (en) | 2016-12-22 | 2022-09-07 | Incyte Corporation | Benzooxazole derivatives as immunomodulators |
MY197501A (en) | 2016-12-22 | 2023-06-19 | Incyte Corp | Tetrahydro imidazo[4,5-c]pyridine derivatives as pd-l1 internalization inducers |
MA47120A (fr) | 2016-12-22 | 2021-04-28 | Incyte Corp | Dérivés pyridine utilisés en tant qu'immunomodulateurs |
DK3572412T3 (da) * | 2017-01-22 | 2021-05-25 | Fujian Cosunter Pharmaceutical Co Ltd | Pyridinderivat som ask1-inhibitor og fremgangsmåde til fremstilling samt anvendelse deraf |
WO2018133865A1 (zh) * | 2017-01-22 | 2018-07-26 | 福建广生堂药业股份有限公司 | Ask1抑制剂及其制备方法和应用 |
UA126571C2 (uk) | 2017-01-24 | 2022-11-02 | Ай-Маб Байофарма Юес Лімітед | Антитіло до cd73 та його застосування |
EP3580224B1 (en) | 2017-02-07 | 2022-07-13 | Biogen MA Inc. | Ask1 inhibiting agents |
WO2018156901A1 (en) | 2017-02-24 | 2018-08-30 | Gilead Sciences, Inc. | Inhibitors of bruton's tyrosine kinase |
US10370381B2 (en) | 2017-02-24 | 2019-08-06 | Gilead Sciences, Inc. | Inhibitors of bruton'S tyrosine kinase |
WO2018157277A1 (en) * | 2017-02-28 | 2018-09-07 | Eli Lilly And Company | Isoquinolin and naphthydrin compounds |
TW201833108A (zh) * | 2017-03-03 | 2018-09-16 | 大陸商江蘇豪森藥業集團有限公司 | 醯胺類衍生物抑制劑及其製備方法和應用 |
JOP20180017A1 (ar) | 2017-03-14 | 2019-01-30 | Gilead Sciences Inc | مثبط كيناز منظم لإشارة تلاشي خلايا |
WO2018183122A1 (en) * | 2017-03-27 | 2018-10-04 | Sidecar Therapeutics, Inc. | Apoptosis signal-regulating kinase 1 (ask 1) inhibitor compounds |
CA3056925A1 (en) | 2017-03-28 | 2018-10-04 | Gilead Sciences, Inc. | Methods of treating liver disease |
JOP20190221A1 (ar) | 2017-04-05 | 2019-09-23 | Seal Rock Therapeutics Inc | مركبات مثبطات كيناز منظم لإشارات الاستماتة 1 (ask1) واستخداماتها |
EP3609496A1 (en) | 2017-04-12 | 2020-02-19 | Gilead Sciences, Inc. | Methods of treating liver disease |
JOP20180040A1 (ar) | 2017-04-20 | 2019-01-30 | Gilead Sciences Inc | مثبطات pd-1/pd-l1 |
AU2018266911C1 (en) | 2017-05-12 | 2022-10-20 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
US10246439B2 (en) | 2017-05-25 | 2019-04-02 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
US10253018B2 (en) | 2017-05-25 | 2019-04-09 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
WO2018218051A1 (en) * | 2017-05-25 | 2018-11-29 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
CN110770233B (zh) * | 2017-06-19 | 2022-07-26 | 广东东阳光药业有限公司 | 稠合双环类化合物及其在药物中的应用 |
GB201711234D0 (en) * | 2017-07-12 | 2017-08-23 | Galapagos Nv | Pyrrolopyrimidine and pyrrolopyridine derivatives |
TW201908306A (zh) * | 2017-07-18 | 2019-03-01 | 大陸商南京聖和藥業股份有限公司 | 作為ask抑制劑的雜環化合物及其應用 |
EP3284739A1 (de) | 2017-07-19 | 2018-02-21 | Bayer CropScience Aktiengesellschaft | Substituierte (het)arylverbindungen als schädlingsbekämpfungsmittel |
WO2019034096A1 (en) * | 2017-08-17 | 2019-02-21 | Sunshine Lake Pharma Co., Ltd. | FUSED BICYCLIC COMPOUNDS AND THEIR USES IN MEDICINE |
US10597382B2 (en) | 2017-08-28 | 2020-03-24 | Enanta Pharmaceuticals, Inc. | Tetrazole containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
CN109456308B (zh) * | 2017-09-06 | 2022-11-29 | 南京圣和药业股份有限公司 | 作为ask抑制剂的杂环化合物及其应用 |
JP2020533335A (ja) * | 2017-09-08 | 2020-11-19 | フロンセラ ユー.エス. ファーマシューティカルズ エルエルシー | アポトーシスシグナル調節キナーゼ阻害剤およびその使用 |
CN109232538B (zh) * | 2017-10-12 | 2020-07-24 | 深圳市塔吉瑞生物医药有限公司 | 一种1,2,4-三氮唑类化合物 |
CN107793400B (zh) * | 2017-10-31 | 2020-01-31 | 武汉九州钰民医药科技有限公司 | 吡啶类化合物及其在制备治疗肝脏疾病的药物中的应用 |
US11427556B2 (en) | 2017-11-17 | 2022-08-30 | Hepagene Therapeutics (HK) Limited | Urea derivatives as inhibitors of ASK1 |
CN109956928B (zh) * | 2017-12-14 | 2021-07-09 | 四川科伦博泰生物医药股份有限公司 | 吡啶类化合物、其制备方法及用途 |
EP3728283B1 (en) | 2017-12-20 | 2023-11-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3' cyclic dinucleotides with phosphonate bond activating the sting adaptor protein |
AU2018392212B9 (en) | 2017-12-20 | 2021-03-18 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3' cyclic dinucleotides with phosphonate bond activating the STING adaptor protein |
US11434249B1 (en) | 2018-01-02 | 2022-09-06 | Seal Rock Therapeutics, Inc. | ASK1 inhibitor compounds and uses thereof |
CN111655678B (zh) * | 2018-01-05 | 2023-08-22 | 广州市恒诺康医药科技有限公司 | 细胞凋亡信号调节激酶-1抑制剂及其应用 |
SG11202007646UA (en) | 2018-02-13 | 2020-09-29 | Gilead Sciences Inc | Pd-1/pd-l1 inhibitors |
CN110294746B (zh) * | 2018-03-21 | 2023-01-31 | 山东轩竹医药科技有限公司 | 一种新的ask1抑制剂及其应用 |
CN110294742B (zh) * | 2018-03-21 | 2023-01-31 | 山东轩竹医药科技有限公司 | 并环类ask1抑制剂及其应用 |
CR20200520A (es) | 2018-03-30 | 2021-03-09 | Incyte Corp | Compuestos heterocíclicos como inmunomoduladores |
TWI818007B (zh) | 2018-04-06 | 2023-10-11 | 捷克科學院有機化學與生物化學研究所 | 2'3'-環二核苷酸 |
TWI833744B (zh) | 2018-04-06 | 2024-03-01 | 捷克科學院有機化學與生物化學研究所 | 3'3'-環二核苷酸 |
TW202005654A (zh) | 2018-04-06 | 2020-02-01 | 捷克科學院有機化學與生物化學研究所 | 2,2,─環二核苷酸 |
US10919911B2 (en) | 2018-04-12 | 2021-02-16 | Terns, Inc. | Tricyclic ASK1 inhibitors |
TWI712412B (zh) | 2018-04-19 | 2020-12-11 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
CN110407806B (zh) * | 2018-04-28 | 2021-08-17 | 深圳微芯生物科技股份有限公司 | 甲酰胺类化合物、其制备方法及其应用 |
JP7328254B2 (ja) * | 2018-05-02 | 2023-08-16 | エナンタ ファーマシューティカルズ インコーポレイテッド | アポトーシスシグナル調節キナーゼ1阻害剤を含むテトラゾール及びその使用方法 |
WO2019213239A1 (en) | 2018-05-02 | 2019-11-07 | Enanta Pharmaceuticals Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
WO2019211799A1 (en) | 2018-05-03 | 2019-11-07 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 2'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide |
JP2021523151A (ja) | 2018-05-11 | 2021-09-02 | ホスホレックス、インコーポレイテッド | 負の表面電荷を有するマイクロ粒子及びナノ粒子 |
EP3790877B1 (en) | 2018-05-11 | 2023-03-01 | Incyte Corporation | Tetrahydro-imidazo[4,5-c]pyridine derivatives as pd-l1 immunomodulators |
CR20200544A (es) | 2018-05-14 | 2021-02-11 | Gilead Sciences Inc | Inhibidores de mcl-1 |
CA3104662A1 (en) * | 2018-06-27 | 2020-01-02 | Biogen Ma Inc. | Ask1 inhibiting agents |
US10654833B2 (en) | 2018-06-28 | 2020-05-19 | Hepatikos Therapeutics, Llc | ASK1 isoindolin-1-one inhibitors and methods of use thereof |
TWI732245B (zh) | 2018-07-13 | 2021-07-01 | 美商基利科學股份有限公司 | Pd‐1/pd‐l1抑制劑 |
EP3825315B1 (en) * | 2018-07-20 | 2022-08-31 | Fujian Akeylink Biotechnology Co., Ltd. | Crystal form as ask1 inhibitor, preparation method therefor, and application thereof |
WO2020030107A1 (zh) * | 2018-08-10 | 2020-02-13 | 江苏豪森药业集团有限公司 | 一种含有酰胺类衍生物的药物组合物及其制备方法和应用 |
CN110818683B (zh) * | 2018-08-10 | 2023-04-14 | 中国科学院上海药物研究所 | 2-吡啶取代脲结构小分子化合物及其合成和应用 |
WO2020034988A1 (zh) * | 2018-08-14 | 2020-02-20 | 江苏豪森药业集团有限公司 | 凋亡信号调节激酶1抑制剂的盐及其晶型 |
WO2020036949A1 (en) * | 2018-08-14 | 2020-02-20 | Biogen Ma Inc. | Ask1 inhibiting agents |
US11897898B2 (en) | 2018-08-14 | 2024-02-13 | Biogen Ma Inc. | Pyridine macrocycle compounds as ASK1 inhibiting agents |
WO2020041417A1 (en) * | 2018-08-22 | 2020-02-27 | Enanta Pharmaceuticals, Inc. | Cycloalkyl-containing apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
TW202024020A (zh) * | 2018-08-29 | 2020-07-01 | 美商錫爾羅克醫療公司 | 治療神經退化性疾病之方法 |
WO2020063727A1 (zh) * | 2018-09-30 | 2020-04-02 | 山东轩竹医药科技有限公司 | 三并环类ask1抑制剂及其应用 |
EP3860717A1 (en) | 2018-10-03 | 2021-08-11 | Gilead Sciences, Inc. | Imidozopyrimidine derivatives |
CN112955435A (zh) | 2018-10-24 | 2021-06-11 | 吉利德科学公司 | Pd-1/pd-l1抑制剂 |
WO2020092528A1 (en) | 2018-10-31 | 2020-05-07 | Gilead Sciences, Inc. | Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity |
JP7460644B2 (ja) | 2018-10-31 | 2024-04-02 | ギリアード サイエンシーズ, インコーポレイテッド | Hpk1阻害剤としての置換6-アザベンゾイミダゾール化合物 |
WO2020106707A1 (en) * | 2018-11-19 | 2020-05-28 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
CN109608441A (zh) * | 2018-12-26 | 2019-04-12 | 都创(上海)医药科技有限公司 | 一种ask1抑制剂的合成工艺 |
DK3911647T3 (da) | 2019-01-15 | 2024-02-26 | Gilead Sciences Inc | Isoxazol-forbindelse som FXR-agonist og farmaceutiske sammensætninger, der omfatter en sådan |
CN113439078B (zh) | 2019-02-19 | 2024-04-23 | 吉利德科学公司 | Fxr激动剂的固体形式 |
EP3935065A1 (en) | 2019-03-07 | 2022-01-12 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 3'3'-cyclic dinucleotide analogue comprising a cyclopentanyl modified nucleotide as sting modulator |
EP3934757B1 (en) | 2019-03-07 | 2023-02-22 | Institute of Organic Chemistry and Biochemistry ASCR, V.V.I. | 2'3'-cyclic dinucleotides and prodrugs thereof |
AU2020231115A1 (en) | 2019-03-07 | 2021-08-26 | Institute Of Organic Chemistry And Biochemistry Ascr, V.V.I. | 3'3'-cyclic dinucleotides and prodrugs thereof |
CN113573700A (zh) | 2019-03-11 | 2021-10-29 | 吉利德科学公司 | 化合物的制剂及其用途 |
WO2020198214A1 (en) | 2019-03-25 | 2020-10-01 | Enanta Pharmaceuticals, Inc. | Apoptosis signal-regulating kinase 1 inhibitors and methods of use thereof |
TW202212339A (zh) | 2019-04-17 | 2022-04-01 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TW202210480A (zh) | 2019-04-17 | 2022-03-16 | 美商基利科學股份有限公司 | 類鐸受體調節劑之固體形式 |
TWI826690B (zh) | 2019-05-23 | 2023-12-21 | 美商基利科學股份有限公司 | 經取代之烯吲哚酮化物及其用途 |
TWI770527B (zh) | 2019-06-14 | 2022-07-11 | 美商基利科學股份有限公司 | Cot 調節劑及其使用方法 |
CA3140708A1 (en) | 2019-06-18 | 2020-12-24 | Helen Horton | Combination of hepatitis b virus (hbv) vaccines and pyridopyrimidine derivatives |
EP3990476A1 (en) | 2019-06-25 | 2022-05-04 | Gilead Sciences, Inc. | Flt3l-fc fusion proteins and methods of use |
TW202115059A (zh) | 2019-08-09 | 2021-04-16 | 美商英塞特公司 | Pd—1/pd—l1抑制劑之鹽 |
AR119594A1 (es) | 2019-08-09 | 2021-12-29 | Gilead Sciences Inc | Derivados de tienopirimidina como inhibidores acc y usos de los mismos |
TW202126652A (zh) | 2019-09-30 | 2021-07-16 | 美商英塞特公司 | 作為免疫調節劑之吡啶并[3,2—d]嘧啶化合物 |
CN118178645A (zh) | 2019-10-18 | 2024-06-14 | 四十七公司 | 用于治疗骨髓增生异常综合征和急性髓系白血病的联合疗法 |
JP2022552748A (ja) | 2019-10-31 | 2022-12-19 | フォーティ セブン, インコーポレイテッド | 抗cd47及び抗cd20による血液癌の治療 |
AU2020385113A1 (en) | 2019-11-11 | 2022-05-19 | Incyte Corporation | Salts and crystalline forms of a PD-1/PD-L1 inhibitor |
TWI778443B (zh) | 2019-11-12 | 2022-09-21 | 美商基利科學股份有限公司 | Mcl1抑制劑 |
EP4058144A1 (en) | 2019-11-15 | 2022-09-21 | Gilead Sciences, Inc. | Triazole carbamate pyridyl sulfonamides as lpa receptor antagonists and uses thereof |
CN111018831B (zh) * | 2019-11-21 | 2022-05-31 | 中国药科大学 | 细胞凋亡信号调节激酶抑制剂及其应用 |
US20230105984A1 (en) | 2019-12-23 | 2023-04-06 | Svetlana Marukian | Compositions and methods for the treatment of liver diseases and disorders |
PE20230376A1 (es) | 2019-12-24 | 2023-03-06 | Carna Biosciences Inc | Compuestos moduladores de la diacilglicerol quinasa |
US11692038B2 (en) | 2020-02-14 | 2023-07-04 | Gilead Sciences, Inc. | Antibodies that bind chemokine (C-C motif) receptor 8 (CCR8) |
AU2021249010A1 (en) | 2020-03-30 | 2022-10-06 | Gilead Sciences, Inc. | Solid forms of (S)-6-(((1-(bicyclo[1.1.1]pentan-1-yl)-1H-1,2,3-triazol-4-yl)2-methyl-1-oxo-1,2- dihydroisoquinolin-5-yl)methyl)))amino)8-chloro-(neopentylamino)quinoline-3-carb onitrile a cot inhibitor compound |
AU2021245924B2 (en) | 2020-04-02 | 2024-02-29 | Gilead Sciences, Inc. | Process for preparing a Cot inhibitor compound |
CR20220547A (es) | 2020-05-01 | 2022-12-15 | Gilead Sciences Inc | Compuestos de 2,4-dioxopirimidina inhibidores de cd73 |
IL298082A (en) | 2020-06-03 | 2023-01-01 | Gilead Sciences Inc | lpa receptor antagonists and uses thereof |
US11702407B2 (en) | 2020-06-03 | 2023-07-18 | Gilead Sciences, Inc. | LPA receptor antagonists and uses thereof |
CN111808079A (zh) * | 2020-08-05 | 2020-10-23 | 中国药科大学 | 吲哚类ask1小分子抑制剂及其制备方法和应用 |
TW202233615A (zh) | 2020-11-06 | 2022-09-01 | 美商英塞特公司 | Pd—1/pd—l1抑制劑之結晶形式 |
CA3200844A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process for making a pd-1/pd-l1 inhibitor and salts and crystalline forms thereof |
WO2022099018A1 (en) | 2020-11-06 | 2022-05-12 | Incyte Corporation | Process of preparing a pd-1/pd-l1 inhibitor |
WO2022192428A1 (en) | 2021-03-11 | 2022-09-15 | Gilead Sciences, Inc. | Glp-1r modulating compounds |
US20230079863A1 (en) | 2021-03-29 | 2023-03-16 | Gilead Sciences, Inc. | Khk inhibitors |
TW202302145A (zh) | 2021-04-14 | 2023-01-16 | 美商基利科學股份有限公司 | CD47/SIRPα結合及NEDD8活化酶E1調節次單元之共抑制以用於治療癌症 |
KR20240005892A (ko) | 2021-05-11 | 2024-01-12 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
KR20240007233A (ko) | 2021-05-13 | 2024-01-16 | 길리애드 사이언시즈, 인코포레이티드 | Lpa 수용체 길항제 및 이의 용도 |
WO2022245671A1 (en) | 2021-05-18 | 2022-11-24 | Gilead Sciences, Inc. | Methods of using flt3l-fc fusion proteins |
TW202304435A (zh) | 2021-06-04 | 2023-02-01 | 美商基利科學股份有限公司 | 治療nash之方法 |
TW202311256A (zh) | 2021-06-18 | 2023-03-16 | 美商基利科學股份有限公司 | 用於治療fxr誘發之搔癢之il-31調節劑 |
CA3222439A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
CN117480155A (zh) | 2021-06-23 | 2024-01-30 | 吉利德科学公司 | 二酰基甘油激酶调节化合物 |
EP4359415A1 (en) | 2021-06-23 | 2024-05-01 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2022271650A1 (en) | 2021-06-23 | 2022-12-29 | Gilead Sciences, Inc. | Diacylglyercol kinase modulating compounds |
WO2023076983A1 (en) | 2021-10-28 | 2023-05-04 | Gilead Sciences, Inc. | Pyridizin-3(2h)-one derivatives |
CA3235986A1 (en) | 2021-10-29 | 2023-05-04 | Gilead Science, Inc. | Cd73 compounds |
WO2023107938A1 (en) | 2021-12-08 | 2023-06-15 | Gilead Sciences, Inc. | Lpa receptor antagonists and uses thereof |
WO2023107956A1 (en) | 2021-12-08 | 2023-06-15 | Dragonfly Therapeutics, Inc. | Proteins binding nkg2d, cd16 and 5t4 |
US20230220106A1 (en) | 2021-12-08 | 2023-07-13 | Dragonfly Therapeutics, Inc. | Antibodies targeting 5t4 and uses thereof |
AU2022417491A1 (en) | 2021-12-22 | 2024-05-23 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
AU2022419982A1 (en) | 2021-12-22 | 2024-06-06 | Gilead Sciences, Inc. | Ikaros zinc finger family degraders and uses thereof |
TW202340168A (zh) | 2022-01-28 | 2023-10-16 | 美商基利科學股份有限公司 | Parp7抑制劑 |
TW202346277A (zh) | 2022-03-17 | 2023-12-01 | 美商基利科學股份有限公司 | Ikaros鋅指家族降解劑及其用途 |
US20230355796A1 (en) | 2022-03-24 | 2023-11-09 | Gilead Sciences, Inc. | Combination therapy for treating trop-2 expressing cancers |
TW202345901A (zh) | 2022-04-05 | 2023-12-01 | 美商基利科學股份有限公司 | 用於治療結腸直腸癌之組合療法 |
TW202400138A (zh) | 2022-04-21 | 2024-01-01 | 美商基利科學股份有限公司 | Kras g12d調節化合物 |
WO2024006929A1 (en) | 2022-07-01 | 2024-01-04 | Gilead Sciences, Inc. | Cd73 compounds |
WO2024059212A2 (en) * | 2022-09-15 | 2024-03-21 | Vanderbilt University | 6,6 western core compounds as mglu5 negative allosteric modulators and methods of making and using the same |
WO2024059216A2 (en) * | 2022-09-15 | 2024-03-21 | Vanderbilt University | 6,6 southwestern core compounds as mglu5 negative allosteric modulators and methods of making and using the same |
WO2024064668A1 (en) | 2022-09-21 | 2024-03-28 | Gilead Sciences, Inc. | FOCAL IONIZING RADIATION AND CD47/SIRPα DISRUPTION ANTICANCER COMBINATION THERAPY |
Family Cites Families (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
CA1121825A (en) | 1978-04-11 | 1982-04-13 | Franco Bolasco | 2-(2-thenoylthio)-propionylglycine: method for its preparation and pharmaceutical formulations containing said compound |
US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
US6159731A (en) | 1997-02-12 | 2000-12-12 | Massachusetts Institute Of Technology | Daxx, a Fas-binding protein that activates JNK and apoptosis |
AUPP285898A0 (en) * | 1998-04-07 | 1998-04-30 | Fujisawa Pharmaceutical Co., Ltd. | Amido derivatives |
DE60039677D1 (de) | 1999-03-19 | 2008-09-11 | Aventis Pharma Inc | Akt-3 nukleinsäure, polypeptide und deren verwendung |
US6881555B2 (en) | 1999-03-19 | 2005-04-19 | Aventis Pharmaceuticals Inc. | AKT nucleic acids, polypeptides, and uses thereof |
US20040087798A1 (en) * | 2000-03-14 | 2004-05-06 | Akira Yamada | Novel amide compounds |
WO2002038179A1 (fr) * | 2000-11-10 | 2002-05-16 | Kissei Pharmaceutical Co., Ltd. | Preventifs ou remedes de maladies du reticulum endoblastique liees au stress |
US20040110785A1 (en) | 2001-02-02 | 2004-06-10 | Tao Wang | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives |
US20070237770A1 (en) | 2001-11-30 | 2007-10-11 | Albert Lai | Novel compositions and methods in cancer |
TW200400818A (en) | 2002-05-21 | 2004-01-16 | Wyeth Corp | Method for the use of pyranoindole derivatives to treat infection with hepatitis C virus |
TW200400963A (en) | 2002-05-21 | 2004-01-16 | Wyeth Corp | R-enantiomers of pyranoindole derivatives and the use thereof for the treatment of hepatitis C virus infection or disease |
EP1661581A1 (en) | 2003-07-28 | 2006-05-31 | Osaka Industrial Promotion Organization | Remedy for cardiac failure comprising ask1 inhibitor as the active ingredient and method of screening the same |
TW200526626A (en) | 2003-09-13 | 2005-08-16 | Astrazeneca Ab | Chemical compounds |
GB0324551D0 (en) | 2003-10-21 | 2003-11-26 | Karobio Ab | Novel compounds |
US7078064B2 (en) | 2003-12-03 | 2006-07-18 | George Zabrecky | Compositions and methods useful for treating and preventing chronic liver disease, chronic HCV infection and non-alcoholic steatohepatitis |
EP1794137A4 (en) | 2004-09-27 | 2009-12-02 | Kosan Biosciences Inc | SPECIFIC KINASE INHIBITORS |
CA2586870A1 (en) * | 2004-11-10 | 2006-05-18 | Synta Pharmaceuticals Corp. | Il-12 modulatory compounds |
CA2591413A1 (en) | 2004-12-16 | 2006-06-22 | Vertex Pharmaceuticals Incorporated | Pyrid-2-ones useful as inhibitors of tec family protein kinases for the treatment of inflammatory, proliferative and immunologically-mediated diseases |
EP1677113A1 (en) | 2004-12-29 | 2006-07-05 | Max-Delbrück-Centrum für Molekulare Medizin (MDC) | Method for the identification of protein-protein interactions in disease related protein networks |
US20070276050A1 (en) | 2006-02-27 | 2007-11-29 | Gilead Sciences, Inc. | Methods for identifying ASK1 inhibitors useful for preventing and/or treating cardiovascular diseases |
JP2009544625A (ja) | 2006-07-20 | 2009-12-17 | メーメット・カーラマン | Rhoキナーゼのベンゾチオフェン阻害剤 |
US20100029619A1 (en) | 2006-08-04 | 2010-02-04 | Takeda Pharmaceutical Company Limted | Fused heterocyclic compound |
WO2008042867A2 (en) | 2006-09-29 | 2008-04-10 | Emiliem Inc. | Modulators of multiple kinases |
AU2007333106A1 (en) | 2006-12-08 | 2008-06-19 | Asuragen, Inc. | miR-20 regulated genes and pathways as targets for therapeutic intervention |
WO2009011850A2 (en) | 2007-07-16 | 2009-01-22 | Abbott Laboratories | Novel therapeutic compounds |
EP2181112A1 (en) | 2007-08-31 | 2010-05-05 | Merck Serono S.A. | Triazolopyridine compounds and their use as ask inhibitors |
EP2227471A1 (en) | 2007-12-11 | 2010-09-15 | Schering Corporation | Gamma secretase modulators |
EP2271646A1 (en) | 2008-03-31 | 2011-01-12 | Takeda Pharmaceutical Company Limited | Apoptosis signal-regulating kinase 1 inhibitors |
US8178555B2 (en) | 2008-06-24 | 2012-05-15 | Takeda Pharmaceutical Company Limited | Apoptosis signal-regulating kinase 1 inhibitors |
US20110263441A1 (en) | 2008-10-15 | 2011-10-27 | Golub Todd R | Compositions, kits, and methods for identification, assessment, prevention, and therapy of hepatic disorders |
US20110294693A1 (en) | 2008-11-17 | 2011-12-01 | The George Washington University | Compositions and Methods for Identifying Autism Spectrum Disorders |
PA8854101A1 (es) | 2008-12-18 | 2010-07-27 | Ortho Mcneil Janssen Pharm | Derivados de imidazol bicíclicos sustituidos como moduladores de gamma secretasa |
EP2411516A1 (en) | 2009-03-27 | 2012-02-01 | Merck Sharp&Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA) |
TWI625121B (zh) | 2009-07-13 | 2018-06-01 | 基利科學股份有限公司 | 調節細胞凋亡信號之激酶的抑制劑 |
WO2011041293A1 (en) | 2009-09-30 | 2011-04-07 | Takeda Pharmaceutical Company Limited | Pyrazolo [1, 5-a] pyrimidine derivatives as apoptosis signal-regulating kinase 1 inhibitors |
PL2531501T3 (pl) | 2010-02-03 | 2014-05-30 | Takeda Pharmaceuticals Co | Inhibitory kinazy 1 regulującej sygnał apoptotyczny |
WO2011097594A2 (en) | 2010-02-08 | 2011-08-11 | Kinagen, Inc. | Therapeutic methods and compositions involving allosteric kinase inhibition |
ES2677356T3 (es) | 2010-03-24 | 2018-08-01 | Amitech Therapeutics Solutions, Inc. | Compuestos heterocíclicos útiles para la inhibición de quinasas |
AU2011272782B2 (en) | 2010-07-02 | 2014-11-27 | Gilead Sciences, Inc. | Apoptosis signal-regulating kinase inhibitors |
TW201300380A (zh) | 2010-10-19 | 2013-01-01 | Comentis Inc | 抑制β-分泌酶活性之噁二唑化合物及其使用方法 |
US20130236441A1 (en) | 2010-11-18 | 2013-09-12 | University Of Delaware | Methods of treating and preventing thrombotic diseases using ask1 inhibitors |
US9045485B2 (en) | 2010-12-16 | 2015-06-02 | Convergence Pharmaceuticals Limited | ASK 1 inhibiting pyrrolopyrimidine derivatives |
CA2827894A1 (en) | 2011-02-22 | 2012-08-30 | Caris Life Sciences Luxembourg Holdings, S.A.R.L. | Circulating biomarkers |
JP2014526032A (ja) | 2011-06-07 | 2014-10-02 | カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス.アー.エール.エル. | 癌に対する循環バイオマーカー |
TWI478908B (zh) | 2011-07-01 | 2015-04-01 | Gilead Sciences Inc | 作為離子通道調節劑之稠合雜環化合物 |
EP2545964A1 (en) | 2011-07-13 | 2013-01-16 | Phenex Pharmaceuticals AG | Novel FXR (NR1H4) binding and activity modulating compounds |
SI2776038T1 (en) | 2011-11-11 | 2018-06-29 | Gilead Apollo, Llc | ACC INHIBITORS AND THEIR USE |
UY34573A (es) | 2012-01-27 | 2013-06-28 | Gilead Sciences Inc | Inhibidor de la quinasa que regula la señal de la apoptosis |
UY35212A (es) | 2012-12-21 | 2014-06-30 | Gilead Sciences Inc | Inhibidores de la quinasa que regula la señal de la apoptosis |
US9169243B2 (en) | 2013-12-20 | 2015-10-27 | Gilead Sciences, Inc. | Apoptosis signal-regulating kinase inhibitors |
CN103896990B (zh) | 2014-03-12 | 2017-02-08 | 石家庄诚志永华显示材料有限公司 | 有机电致发光材料及其应用 |
WO2015187499A1 (en) | 2014-06-03 | 2015-12-10 | Gilead Sciences, Inc. | Use of an ask1 inhibitor for the treatment of liver disease, optionally in combination with a loxl2 inhibitor |
SG11201701723XA (en) | 2014-09-24 | 2017-04-27 | Gilead Sciences Inc | Methods of treating liver disease |
EP3034499A1 (en) | 2014-12-17 | 2016-06-22 | Gilead Sciences, Inc. | Novel FXR (NR1H4) modulating compounds |
MA41252A (fr) | 2014-12-23 | 2017-10-31 | Gilead Sciences Inc | Formes solides d'un inhibiteur d'ask 1 |
PL3237404T3 (pl) | 2014-12-23 | 2021-05-04 | Gilead Sciences, Inc. | Procesy wytwarzania inhibitorów ask1 |
CA2972919A1 (en) | 2015-01-09 | 2016-07-14 | Gilead Apollo, Llc | Acc inhibitor combination therapy for the treatment of non-alcoholic fatty liver disease |
CA3155220C (en) | 2016-03-02 | 2024-01-16 | Gilead Apollo, Llc | Solid forms of a thienopyrimidinedione acc inhibitor and methods for production thereof |
ES2921432T3 (es) | 2016-06-13 | 2022-08-25 | Gilead Sciences Inc | Derivados de azetidina como moduladores de FXR (NR1H4) |
CA2968836A1 (en) | 2016-06-13 | 2017-12-13 | Gilead Sciences, Inc. | Fxr (nr1h4) modulating compounds |
CA3042398A1 (en) | 2016-11-11 | 2018-05-17 | Gilead Sciences, Inc. | Methods of treating liver disease |
JOP20180017A1 (ar) | 2017-03-14 | 2019-01-30 | Gilead Sciences Inc | مثبط كيناز منظم لإشارة تلاشي خلايا |
ES2927019T3 (es) | 2017-03-28 | 2022-11-02 | Gilead Sciences Inc | Combinaciones terapéuticas para el tratamiento de enfermedades hepáticas |
CA3056925A1 (en) | 2017-03-28 | 2018-10-04 | Gilead Sciences, Inc. | Methods of treating liver disease |
EP3609496A1 (en) | 2017-04-12 | 2020-02-19 | Gilead Sciences, Inc. | Methods of treating liver disease |
TWI814744B (zh) | 2017-10-06 | 2023-09-11 | 美商基利科學股份有限公司 | 包含acc抑制劑之組合療法 |
-
2010
- 2010-07-06 TW TW106124595A patent/TWI625121B/zh active
- 2010-07-06 TW TW104112851A patent/TWI598347B/zh active
- 2010-07-06 TW TW099122220A patent/TWI491606B/zh active
- 2010-07-12 ME MEP-2015-53A patent/ME02104B/me unknown
- 2010-07-12 AR ARP100102515A patent/AR077564A1/es active IP Right Grant
- 2010-07-12 PL PL17208659T patent/PL3363797T3/pl unknown
- 2010-07-12 HU HUE15151030A patent/HUE038529T2/hu unknown
- 2010-07-12 US US12/834,673 patent/US8378108B2/en active Active
- 2010-07-12 PT PT151510302T patent/PT2933252T/pt unknown
- 2010-07-12 DK DK15151030.2T patent/DK2933252T3/en active
- 2010-07-12 KR KR1020177018101A patent/KR20170081722A/ko not_active Application Discontinuation
- 2010-07-12 ES ES15151030T patent/ES2662397T3/es active Active
- 2010-07-12 SI SI201031622T patent/SI2933252T1/en unknown
- 2010-07-12 RS RS20150247A patent/RS53951B1/en unknown
- 2010-07-12 SI SI201032055T patent/SI3363797T1/sl unknown
- 2010-07-12 JP JP2012520706A patent/JP5745721B2/ja active Active
- 2010-07-12 ES ES10733116.7T patent/ES2533796T3/es active Active
- 2010-07-12 EP EP15151030.2A patent/EP2933252B1/en active Active
- 2010-07-12 CN CN201080040457.5A patent/CN102482257B/zh active Active
- 2010-07-12 EP EP10733116.7A patent/EP2454250B1/en active Active
- 2010-07-12 SI SI201030851T patent/SI2454250T1/sl unknown
- 2010-07-12 EP EP20210819.7A patent/EP3858824A1/en active Pending
- 2010-07-12 WO PCT/US2010/041739 patent/WO2011008709A1/en active Application Filing
- 2010-07-12 CA CA2767894A patent/CA2767894C/en active Active
- 2010-07-12 KR KR1020187018679A patent/KR20180077338A/ko not_active Application Discontinuation
- 2010-07-12 AU AU2010273597A patent/AU2010273597B2/en active Active
- 2010-07-12 DK DK10733116T patent/DK2454250T3/en active
- 2010-07-12 PT PT172086597T patent/PT3363797T/pt unknown
- 2010-07-12 MX MX2012000708A patent/MX2012000708A/es active IP Right Grant
- 2010-07-12 BR BR112012000894A patent/BR112012000894A2/pt not_active Application Discontinuation
- 2010-07-12 KR KR1020127000966A patent/KR101755524B1/ko active IP Right Grant
- 2010-07-12 EP EP17208659.7A patent/EP3363797B8/en active Active
- 2010-07-12 NO NO15151030A patent/NO2933252T3/no unknown
- 2010-07-12 NZ NZ597533A patent/NZ597533A/en unknown
- 2010-07-12 LT LTEP15151030.2T patent/LT2933252T/lt unknown
- 2010-07-12 PL PL10733116T patent/PL2454250T3/pl unknown
- 2010-07-12 RS RS20180292A patent/RS56981B1/sr unknown
- 2010-07-12 PT PT107331167T patent/PT2454250E/pt unknown
- 2010-07-12 PL PL15151030T patent/PL2933252T3/pl unknown
- 2010-07-12 ES ES17208659T patent/ES2854710T3/es active Active
- 2010-07-13 UY UY0001032786A patent/UY32786A/es not_active Application Discontinuation
-
2012
- 2012-09-13 US US13/615,259 patent/US8552196B2/en not_active Ceased
- 2012-09-14 US US13/618,841 patent/US8598360B2/en active Active
- 2012-11-07 HK HK12111231.2A patent/HK1170482A1/xx unknown
-
2013
- 2013-07-02 US US13/934,020 patent/US9067933B2/en active Active
-
2015
- 2015-02-17 HR HRP20150185AT patent/HRP20150185T1/hr unknown
- 2015-03-03 JP JP2015040924A patent/JP2015098500A/ja not_active Withdrawn
- 2015-04-13 SM SM201500090T patent/SMT201500090B/xx unknown
- 2015-05-19 US US14/716,526 patent/US9586932B2/en active Active
-
2016
- 2016-04-18 HK HK16104397.3A patent/HK1216426A1/zh unknown
-
2017
- 2017-01-19 JP JP2017007269A patent/JP2017071647A/ja not_active Withdrawn
- 2017-01-23 US US15/413,101 patent/US20170196844A1/en not_active Abandoned
-
2018
- 2018-03-07 CY CY20181100283T patent/CY1119889T1/el unknown
- 2018-03-09 HR HRP20180413TT patent/HRP20180413T1/hr unknown
- 2018-08-01 JP JP2018144888A patent/JP2018184464A/ja active Pending
-
2019
- 2019-08-01 US US16/529,631 patent/USRE48711E1/en active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HRP20180413T1 (hr) | Inhibitori kinaza koji reguliraju signalne puteve u apoptozi | |
JP2012532931A5 (hr) | ||
CA2915561C (en) | Novel substituted bicyclic compounds as bromodomain inhibitors | |
US8188113B2 (en) | Dihydropyridopyrimidinyl, dihydronaphthyidinyl and related compounds useful as kinase inhibitors for the treatment of proliferative diseases | |
US9861637B2 (en) | Heterocyclic compounds as bromodomain inhibitors | |
ES2806135T3 (es) | Nuevos inhibidores de bromodominios bicíclicos | |
RU2018123779A (ru) | Новые соединения | |
JP6117235B2 (ja) | Pi3kの活性または機能の阻害剤の使用 | |
CA3118934A1 (en) | Pyridazinone compounds and uses thereof | |
JP2011520915A5 (hr) | ||
WO2012087938A1 (en) | Quinazolinone derivatives as antiviral agents | |
CN105120869A (zh) | 眼部病症的治疗 | |
KR20140043452A (ko) | 치환된 퀴놀린 및 이의 약제로서의 용도 | |
JP2017516830A (ja) | ピラゾール化合物及びt型カルシウムチャンネルブロッカーとしてのそれらの使用 | |
JP2021505598A5 (hr) | ||
KR20150013180A (ko) | Ttx-s 차단제로서 아미드 유도체 | |
JP2021521142A (ja) | Crhr2拮抗薬としての縮合環状尿素誘導体 | |
ES2661585T3 (es) | Derivados de pirazolopiridina como bloqueadores de TTX-S |